Schizophrenia And Related Disorders
Schizophrenia and related disorders are a group of chronic psychiatric conditions characterized by disturbances in thought, perception, affect, and behavior, including symptoms such as delusions, hallucinations, disorganized thinking, and negative symptoms.
Schizophrenia — let's break down the name: "schizo" (Greek: split) + "phrēn" (Greek: mind). This does not mean "split personality" (a common misconception), but rather a splitting or fragmentation of mental functions — thought, perception, emotion, and behaviour become disconnected from each other.
Schizophrenia is a chronic, severe neuropsychiatric disorder characterised by a constellation of positive symptoms (psychosis — delusions, hallucinations), negative symptoms (loss of normal functioning — avolition, flat affect), disorganisation (thought disorder, bizarre behaviour), cognitive impairment, and affective disturbance. It is the prototypical psychotic disorder, and it profoundly impairs social and occupational functioning [1][2].
"Related psychoses" encompass a spectrum of disorders that share psychotic features but differ in duration, prominence of mood symptoms, or restriction to specific delusional themes. These include:
- Schizophreniform disorder (schizophrenia-like but < 6 months)
- Schizoaffective disorder (schizophrenia + major mood episode occurring concurrently)
- Delusional disorder (non-bizarre, encapsulated delusions without other schizophrenia features)
- Brief psychotic disorder (psychotic symptoms lasting < 1 month)
- Substance/medication-induced psychotic disorder
- Psychotic disorder due to another medical condition
Key Conceptual Point
Schizophrenia is best understood as a neurodevelopmental disorder with a stress-vulnerability model — genetic liability creates a vulnerable brain, and environmental insults (prenatal, childhood, adolescence) push it past a threshold into frank psychosis. It is NOT a neurodegenerative disease like Alzheimer's, even though there are progressive structural brain changes in a subgroup of patients [1][2].
2. Epidemiology
- Prevalence of all psychotic disorders: approximately 2–3% [1]
- Lifetime risk of developing schizophrenia: ~1% [1]
- Median incidence rate of schizophrenia: 15.2 per 100,000 per year [1]
- Lifetime prevalence of psychotic disorders in Hong Kong: 2.5% (Chang et al. 2017) [1]
- Schizophrenia is traditionally described as a high-prevalence, low-incidence disease — meaning it is relatively common in the population at any given time (because it is chronic), but new cases per year are not that many [2]
| Parameter | Detail |
|---|---|
| Male-to-female risk ratio | 1.4:1 [1] |
| Age of onset | Late adolescence and early adulthood [1] |
| Age of onset (M) | 18–25 years [2] |
| Age of onset (F) | Bimodal: 25–35 years + perimenopausal peak [2] |
| Men vs Women | Men have an earlier age at onset of psychosis than women [1] |
| Gender severity | Males tend to have more severe illness, more negative symptoms, poorer outcomes [2] |
Why the gender difference in onset? Oestrogen is thought to have a neuroprotective/antidopaminergic effect — it raises the threshold for psychosis. This is why women develop schizophrenia later (while oestrogen is high) and have a second peak at perimenopause (when oestrogen drops).
Incidence rates varied widely across regions (7.7–43 per 100,000 per year) [1], with elevated incidence being associated with:
- Migrants of ethnic minority (from developing countries to western developed countries, e.g. UK, Netherlands) (vs locally-born Caucasians) [1]
- Individuals being brought up in urban (vs rural) areas (urbanicity) [1]
These observations support the social defeat hypothesis / stress-dopamine sensitisation — chronic social stress (discrimination, social exclusion, isolation) sensitises the mesolimbic dopamine system, lowering the threshold for psychosis [1].
- Suicide is the single largest cause of premature death in schizophrenia [2]
- Reduced lifespan by 10–15 years on average [2]
- 2.6× all-cause mortality, the majority being non-suicidal causes [2]
- Reasons: (1) Sedentary lifestyle, poor nutrition; (2) High rates of smoking, substance/alcohol abuse; (3) Metabolic syndrome from 2nd-generation antipsychotics; (4) Possibly inherent disease process accelerating aging and medical morbidity [2]
- No. 12 leading disability worldwide, accounting for substantial direct and indirect costs [2]
Exam Pearl
Students often forget that the majority of excess mortality in schizophrenia is from cardiovascular and metabolic disease, NOT suicide. However, suicide is the single largest specific cause of premature death. The overall excess mortality is driven by multiple medical causes combined.
3. Anatomy and Functional Neuroanatomy
Understanding schizophrenia requires understanding the dopamine pathways and the key brain regions affected.
This is the anatomical backbone of the dopamine hypothesis and explains both the symptoms and the side effects of treatment.
| Pathway | Origin → Destination | Function | Relevance to Schizophrenia |
|---|---|---|---|
| Mesolimbic | Ventral tegmental area (VTA) → Nucleus accumbens, amygdala, hippocampus | Reward, motivation, salience | Hyperdopaminergic → positive symptoms (delusions, hallucinations) [1] |
| Mesocortical | VTA → Prefrontal cortex (PFC) | Executive function, working memory, motivation | Hypodopaminergic → negative symptoms & cognitive deficits [1] |
| Nigrostriatal | Substantia nigra → Dorsal striatum (caudate, putamen) | Voluntary motor control | Antipsychotic blockade here → extrapyramidal side effects (EPS) [1] |
| Tuberoinfundibular | Hypothalamus → Anterior pituitary | Inhibits prolactin release | Antipsychotic blockade here → hyperprolactinaemia [1] |
Why does dopamine blockade in the nigrostriatal pathway cause EPS? Dopamine in the basal ganglia normally facilitates smooth, coordinated movement by modulating the direct and indirect pathways of motor control. When antipsychotics block D2 receptors here, the result is an imbalance favouring the indirect (inhibitory) pathway — clinically manifesting as parkinsonian features (rigidity, bradykinesia, tremor), akathisia, and dystonia.
Structural / neuroanatomical abnormalities in schizophrenia (by sMRI) [1]:
- Reduced whole brain volume / grey matter (GM) volume [1]
- Reduced GM volumes in temporal lobe (hippocampus, amygdala, superior temporal gyri [STG]), prefrontal cortex, thalamus, anterior cingulate [1]
- Increased ventricular volume [1]
- Reduced cortical thickness (cortical thinning) [1]
- Reduced cortical surface area [1]
| Brain Region | Normal Function | Consequence of Abnormality in Schizophrenia |
|---|---|---|
| Prefrontal cortex | Executive function, working memory, planning, social cognition | Negative symptoms, cognitive deficits, poor insight |
| Temporal lobe / STG | Language comprehension (Wernicke's area), auditory processing | Auditory verbal hallucinations |
| Hippocampus | Memory formation, contextual processing | Memory impairment, inability to contextualise stimuli → delusional interpretation |
| Amygdala | Emotion processing, fear conditioning | Affective dysregulation, paranoia |
| Thalamus | Sensory relay, gating of information | Sensory overload → inability to filter relevant from irrelevant stimuli |
| Anterior cingulate | Error monitoring, conflict resolution, motivation | Avolition, impaired self-monitoring |
Structural & functional connectivity alterations [1]:
- Altered integrity of white matter tracts (via DTI — diffusion tensor imaging) [1]
- Altered resting-state functional connectivity (via fMRI) [1]
Why does disconnectivity matter? Schizophrenia is increasingly understood as a disconnection syndrome — the problem isn't just in individual brain regions, but in how they communicate with each other. This explains the bizarre juxtaposition of symptoms: a patient can have intact memory for facts but completely disordered thinking — the "wires" between brain areas are disrupted.
Evidence indicates progressive structural brain changes (volume reduction) across the course of illness, at least in a subgroup of patients [1].
4. Aetiology
Schizophrenia follows a multifactorial, gene–environment interaction model. Think of it as a stress-vulnerability framework: genes load the gun, environment pulls the trigger.
High degree of heritability (estimated as 80% contributed by genetic cause) [1]
| Relationship | Risk |
|---|---|
| General population | ~1% |
| First-degree relatives | 10–15% [1] |
| Dizygotic twin | ~17% [2] |
| Monozygotic twin | ~50% [1] |
| Both parents affected | ~46% |
The MZ concordance of ~50% (not 100%) is critical — it proves that genetics alone is NOT sufficient. Environmental factors must also be involved [2].
Polygenic (multiple genes with small effects contributed by each gene) [1]:
- Many identified candidate genes are related to dopamine, glutamate, synaptic functions, and immune mechanisms [1]
- Single nucleotide polymorphisms (SNPs): common variants conferring small individual risks; 108+ genomic loci identified, including the MHC locus on chromosome 6 (immune function) [2]
Rare copy number variants (CNVs) with larger effect [1]:
- e.g. Chromosome 22q11.2 deletion syndrome (DiGeorge Syndrome or Velo-cardio-facial syndrome, VCFS) [1]
- Associated with 20–30-fold increase in risk of schizophrenia [1]
Why Ch22q11.2 deletion? This deletion encompasses genes involved in neuronal migration, synaptic signalling, and catecholamine metabolism (including COMT — catechol-O-methyltransferase, which degrades dopamine). Loss of COMT may lead to dopamine dysregulation. Additionally, the resulting congenital anomalies (cardiac defects, palatal abnormalities, thymic hypoplasia) reflect the broader neurodevelopmental disruption.
Schizophrenia shares genetic risk with other schizophrenia-spectrum disorders: schizoaffective disorder, schizotypal personality disorder, paranoid personality disorder, and even bipolar disorder and autism [2][3].
4.2 Environmental Factors
- Obstetric complications — hypoxic-ischaemic injury to the developing brain, particularly the hippocampus (exquisitely sensitive to hypoxia)
- Winter birth, maternal infections (e.g. influenza, toxoplasmosis) — maternal immune activation causes cytokine-mediated disruption of fetal brain development. The winter birth effect correlates with peak influenza season
- Advanced paternal age at conception (de novo mutation / epigenetic) — older sperm accumulate more mutations; epigenetic changes (e.g. altered DNA methylation) may also play a role
- Substance abuse (cannabis) — cannabis (specifically THC) increases dopamine release in the mesolimbic pathway. Adolescent cannabis use during the critical period of synaptic pruning is particularly risky; dose-response relationship demonstrated
- Migration (ethnic minority) — chronic social defeat, discrimination, and social isolation sensitise the dopamine system
- Urbanicity (urban upbringing) — related to social fragmentation, pollution, and chronic stress
These proximal social factors are explained by the social defeat hypothesis / stress-dopamine sensitisation [1] — chronic social stress causes the mesolimbic dopamine system to become hyper-responsive, lowering the threshold for psychosis.
- Childhood adversity — abuse, neglect, bullying → chronic HPA axis activation, dopamine sensitisation
- Expressed emotion (EE): critical, hostile, or emotionally over-involved attitudes from family members. Exposure to high-EE environments > 35 hours/week increases relapse risk. This is a perpetuating factor, not a cause [2]
Gene × environment interactions [1] — genetic vulnerability modifies the impact of environmental exposures (e.g., individuals with certain COMT polymorphisms are more susceptible to cannabis-induced psychosis).
The Stress-Vulnerability Model
Think of each person as having a "bucket" of vulnerability. Genetics fills the bucket partially. Each environmental insult adds more. Once the bucket overflows, psychosis emerges. Some people have very full buckets genetically (e.g. 22q11.2 deletion) and need only a small environmental push. Others have nearly empty buckets and would need overwhelming stress to develop psychosis. This explains why not everyone with risk factors gets schizophrenia.
4.3 Neurobiology / Pathophysiology
Dopamine hypothesis [1]:
- Increased pre-synaptic dopamine synthesis in the striatum [1]
- Hyperdopaminergic transmission → manifestations of psychosis [1]
Evidence supporting this:
- All effective antipsychotics block D2 receptors — their clinical potency correlates with D2 binding affinity
- Dopamine-releasing drugs (amphetamines, L-DOPA) can induce psychotic symptoms
- PET imaging shows increased presynaptic dopamine synthesis capacity and release in the striatum of schizophrenia patients
The four dopamine pathways (detailed in Section 3.1) explain the full clinical picture:
| Pathway | State in Schizophrenia | Clinical Consequence |
|---|---|---|
| Mesolimbic | Hyperdopaminergic | Positive symptoms [1] |
| Mesocortical | Hypodopaminergic | Negative & cognitive symptoms [1] |
| Nigrostriatal | Normal (until antipsychotic given) | Antipsychotic-induced parkinsonism / EPS [1] |
| Tuberoinfundibular | Normal (until antipsychotic given) | Hyperprolactinaemia [1] |
Why is there HYPER-dopaminergic transmission in the mesolimbic pathway but HYPO-dopaminergic in the mesocortical pathway at the same time? This is the dopamine paradox. The current model suggests that cortical dopamine deficiency (mesocortical) actually drives subcortical dopamine excess (mesolimbic) — the prefrontal cortex normally exerts inhibitory control over subcortical dopamine release. When the PFC is hypofunctional (due to developmental insults, glutamate dysfunction), this "brake" is lost, leading to disinhibited mesolimbic dopamine firing.
Other neurotransmitters involved: glutamate (NMDA hypofunction), GABA [1]:
Glutamate (NMDA receptor hypofunction hypothesis):
- Excess glutamate neurotransmission → neurotoxicity / may lead to hyperdopaminergia [1]
- NMDA receptor antagonists (phencyclidine/PCP, ketamine) can induce a schizophrenia-like psychosis that includes both positive AND negative symptoms — unlike amphetamines which mainly produce positive symptoms. This makes the glutamate hypothesis more comprehensive [2]
- NMDA hypofunction on GABAergic interneurons → loss of inhibitory tone → excess glutamate release → downstream excessive dopamine release in mesolimbic pathway
Serotonin (5-HT):
- Reduced 5-HT2A and 5-HT1A receptor densities in the frontal cortex [2]
- LSD (a 5-HT2 agonist) is a hallucinogen — supporting serotonin's role
- Atypical antipsychotics (e.g. clozapine, olanzapine) act as 5-HT2A antagonists, which may account for their improved efficacy against negative symptoms and reduced EPS
GABA:
Neuropathological findings [1]:
- Absence of gliosis (glial scarring that would indicate neurodegeneration or post-natal injury)
- Lack of evidence of neuronal loss
- Reduction in synapse-rich neuropil (the dense network of dendrites, axons, and synapses)
- This pattern argues against the neurodegeneration hypothesis [1]
Why is the absence of gliosis so important? In neurodegenerative diseases (Alzheimer's, Parkinson's), neuronal death triggers reactive gliosis — astrocytes and microglia proliferate to clean up debris. The absence of gliosis in schizophrenia suggests the pathology occurred before the brain's glial response system was mature — i.e., during fetal development, supporting a neurodevelopmental origin.
Neurodevelopmental hypothesis — the major hypothesis based on current findings [1][2]:
Schizophrenia is primarily a neurodevelopmental disorder rather than an acquired/neurodegenerative one.
- Motor function deficits occur before onset of illness [1]
- Neurological soft signs (subtle motor and sensory integration abnormalities present premorbidly) [1]
- Poor premorbid adjustment [1]
- Low IQ / mental retardation associated with higher risk of schizophrenia [1]
- Cognitive deficits emerge in prodromal period [1]
- Neurobiology: no gliosis/neuronal loss → prenatal insult; structural brain changes present at or before illness onset, with limited progression after onset [2]
- Most environmental risk factors are pre/perinatal in origin [2]
The conceptual model (from both lecture slides and notes) [1][2]:
Stress-vulnerability model for psychosis development [1] — this integrates all the above: genetic vulnerability + neurodevelopmental insults create a "vulnerable brain" → environmental stressors during adolescence/early adulthood push the system past threshold → psychosis.
Development and course of schizophrenia [1]:
| Phase | Timing | Features |
|---|---|---|
| Premorbid phase | Childhood | Subtle cognitive, motor, social deficits; poor premorbid adjustment; neurological soft signs |
| Prodromal phase (At-Risk Mental State, ARMS / Clinical High-Risk, CHR) | Adolescence & early adulthood | Attenuated psychotic symptoms (unusual ideas, perceptual disturbances), decline in functioning, social withdrawal, cognitive deterioration — NOT yet meeting criteria for frank psychosis |
| First Psychotic Episode (FEP) | Onset of psychosis | Full psychotic symptoms emerge — hallucinations, delusions, disorganisation |
| Longitudinal course | Variable | Three trajectories: (1) Fully recovered; (2) Residual deficits (most common — episodic with incomplete remission); (3) Chronic deteriorating course |
Note that in the prodromal phase: No transition to psychosis is also a possible outcome — not all CHR individuals convert [1].
Duration of Untreated Psychosis (DUP): The time between onset of frank psychotic symptoms and initiation of treatment. Longer DUP is consistently associated with poorer outcomes. This is why early intervention services (e.g. EASY programme in Hong Kong) are critical.
6. Classification
| Disorder | Key Distinguishing Features |
|---|---|
| Schizophrenia | ≥2 of: delusions, hallucinations, disorganised speech, disorganised/catatonic behaviour, negative symptoms (at least one must be delusion, hallucination, or disorganised speech); duration ≥6 months; functional decline |
| Schizophreniform disorder | Same symptoms as schizophrenia but total duration 1–6 months; no requirement for functional decline |
| Schizoaffective disorder | Concurrent major mood episode (depressive or manic) + Criterion A of schizophrenia; ≥2 weeks of delusions/hallucinations WITHOUT mood symptoms during the illness |
| Delusional disorder | ≥1 non-bizarre delusion for ≥1 month; does NOT meet Criterion A of schizophrenia; functioning relatively preserved apart from delusion |
| Brief psychotic disorder | ≥1 psychotic symptom lasting 1 day – 1 month, with full return to premorbid functioning |
| Substance/medication-induced psychotic disorder | Psychosis develops during or soon after substance intoxication/withdrawal |
| Psychotic disorder due to another medical condition | Psychosis directly attributable to a medical condition (e.g. anti-NMDA receptor encephalitis, neurosyphilis, SLE, delirium) |
| Catatonia | Can be associated with another mental disorder, medical condition, or be unspecified |
The old subtypes (paranoid, hebephrenic/disorganised, catatonic, simple, undifferentiated, residual) were removed from DSM-5 due to poor reliability, low diagnostic stability, and limited clinical utility. However, they may still appear in ICD-10 and are worth knowing:
| Subtype | Key Features |
|---|---|
| Paranoid | Prominent delusions (persecutory/grandiose) and hallucinations; relatively preserved cognition and affect; best prognosis among subtypes |
| Hebephrenic (Disorganised) | Prominent disorganised speech and behaviour, flat/inappropriate affect; early onset; worst prognosis |
| Catatonic | Dominated by psychomotor disturbance (stupor, rigidity, waxy flexibility, negativism, excitement) |
| Simple | Insidious negative symptoms without prominent psychosis; progressive decline |
| Residual | Past psychotic episodes, now mainly negative symptoms |
| Undifferentiated | Meets criteria but doesn't fit neatly into other subtypes |
Previously known as paranoid psychoses/paranoia [2]:
- Epidemiology: Uncommon; lifetime risk 0.05–0.1%; median age of onset 46 years [2]
- Clinical features:
- Delusion that is non-bizarre (could theoretically happen in real life), systematised (well-organised, coherent), and single-themed (cf. fragmented, multiple, bizarre in schizophrenia) [2]
- Themes: Persecutory (commonest), erotomania, jealous, somatic, grandiose, mixed, unspecified [2]
- Encapsulated: behaviour unrelated to the delusion is often normal [2]
- No/minimal hallucinations — if present, tend to be fleeting and related to the delusional theme [2]
- No/minimal negative symptoms and impact on functioning [2]
- Course: Acute onset with generally stable trajectory (a proportion goes on to develop full-blown schizophrenia) [2]
DSM-5 Diagnostic Criteria for Delusional Disorder [2]:
- A. ≥1 delusion lasting ≥1 month
- B. Criterion A of schizophrenia has never been met (hallucinations, if present, are not prominent and are related to delusional theme)
- C. Functioning and behaviour are relatively normal apart from the delusion
- D. If mood episodes have occurred, they are brief relative to the delusional periods
- E. Not attributable to substance or medical condition
7. Symptom Dimensions of Schizophrenia
Modern conceptualisation of schizophrenia moves away from simple "positive vs negative" to six symptom dimensions [2]:
7.1 Positive Symptoms — "Reality Distortions"
These represent an excess or distortion of normal brain functions. They are driven by hyperdopaminergic transmission in the mesolimbic pathway [1].
Delusion = a fixed, false belief held with absolute conviction, not amenable to counter-argument, and not explained by the patient's cultural or religious background.
Why do delusions occur? The aberrant salience hypothesis proposes that dopamine dysregulation causes normally irrelevant stimuli to become imbued with inappropriate significance. The patient then constructs delusional explanations to make sense of these abnormally salient experiences.
Common types in schizophrenia:
| Type | Description | Example |
|---|---|---|
| Persecutory | Belief that one is being targeted, harmed, or conspired against | "The government is monitoring me through my phone" |
| Referential | Belief that ordinary events have special personal significance | "The newsreader was sending me a coded message" |
| Grandiose | Belief of inflated worth, power, or identity | "I am the chosen one sent to save humanity" |
| Thought insertion | Belief that thoughts are being placed into one's mind by an external force | "They put these ideas in my head" |
| Thought withdrawal | Belief that thoughts are being removed from one's mind | "Someone is stealing my thoughts" |
| Thought broadcasting | Belief that one's thoughts are transmitted and known to others | "Everyone can hear what I'm thinking" |
| Delusions of control/passivity | Belief that one's actions, feelings, or impulses are controlled by an external force | "They are making my arm move" |
Hallucination = a perception in the absence of an external stimulus, with the quality of a real perception (i.e., the patient believes it is real).
| Modality | Description | Pathophysiology |
|---|---|---|
| Auditory (most common in schizophrenia) | Auditory verbal hallucinations (AVH) — hearing voices | Abnormal activation of the superior temporal gyrus (auditory cortex) + inner speech misattributed to an external source (failure of self-monitoring by prefrontal cortex) |
| Visual | Seeing things not there | More common in organic psychosis (delirium, substance use) — should prompt investigation for organic cause |
| Olfactory | Smelling things not there | Consider temporal lobe epilepsy |
| Tactile | Feeling things on/under the skin | Common in substance-induced psychosis (e.g. formication in stimulant use) |
| Gustatory | Tasting things not there | Rare |
These were historically considered pathognomonic for schizophrenia but are now recognised as highly suggestive but NOT diagnostic (they can occur in other conditions including bipolar disorder with psychosis). Still high-yield for exams. The mnemonic is SPECTRA [2]:
| Letter | Symptom | Explanation |
|---|---|---|
| S | Somatic passivity | Belief that bodily sensations are imposed by external force |
| P | "Made" actions, impulses (Passivity experiences) | Belief that one's will, emotions, or acts are controlled externally |
| E | Thought Echo (écho de la pensée) | Voice repeating one's own thoughts aloud |
| C | Thought Commentary / 3rd person AVH | Voices discussing the patient in the 3rd person, or providing running commentary on their actions |
| T | Thought insertion/withdrawal/broadcasting | Alien thoughts placed in, removed from, or broadcast from one's mind |
| R | Referential delusion / delusional perception | A normal perception given delusional significance (e.g. seeing a red car → believing it's a sign that an assassination will occur) |
| A | Audible thoughts (Gedankenlautwerden) | Patient hears their own thoughts spoken aloud |
These represent a diminution or loss of normal functions. They are linked to hypodopaminergic transmission in the mesocortical pathway [1] and correlate with prefrontal cortex atrophy.
Negative symptoms are often more disabling than positive symptoms and are harder to treat.
The "5 A's" of negative symptoms:
| Symptom | Description | Pathophysiology |
|---|---|---|
| Avolition | Loss of motivation and drive; inability to initiate and sustain purposeful activity | Reduced dopaminergic signalling in mesocortical pathway → impaired reward processing and motivation circuits (prefrontal cortex–striatal loop) |
| Alogia | Poverty of speech (reduced quantity) or poverty of content (speech is vague, repetitive, lacking substance) | Prefrontal cortex dysfunction → impaired language generation |
| Anhedonia | Inability to experience pleasure from previously enjoyable activities | Disrupted reward circuitry involving nucleus accumbens and ventral striatum |
| Asociality | Withdrawal from social interaction; decreased interest in relationships | Combination of amygdala dysfunction (impaired social cognition), prefrontal dysfunction (poor motivation), and possibly secondary to paranoia |
| Affective flattening (blunted affect) | Reduced range and intensity of emotional expression (flat face, monotone voice, poor eye contact) | Prefrontal and temporal lobe dysfunction → impaired emotional expression (NB: the patient may still feel emotions internally — the expression is reduced, not necessarily the experience) |
Primary vs Secondary Negative Symptoms
Before attributing negative symptoms to schizophrenia itself (primary), always rule out secondary causes:
- Depression (can look identical to negative symptoms)
- Antipsychotic side effects (especially EPS — akinesia mimics avolition; sedation mimics alogia)
- Social deprivation (institutional environment)
- Positive symptoms (e.g., patient may be socially withdrawn because of paranoid delusions, not asociality) Distinguishing these has major treatment implications.
7.3 Disorganisation Symptoms — "Disorganised Thoughts and Behaviour"
These represent disrupted integration of thought and behaviour — the "split" in schizophrenia.
The patient's speech reflects their disordered thinking:
| Type | Description | Example |
|---|---|---|
| Loosening of associations (derailment) | Ideas shift from one topic to an unrelated topic without logical connection | "I need to go to the bank. Banks have rivers. Rivers run through it. Running is good exercise." |
| Tangentiality | Replies to questions are obliquely related or completely irrelevant | Q: "How are you feeling?" A: "My dog ate the newspaper yesterday." |
| Incoherence (word salad) | Speech is incomprehensible — words are strung together with no logical or grammatical connection | "Tree window jumps the happy sadly car" |
| Neologisms | Invented words with private meaning | "I'm feeling very snorpelated today" |
| Clang associations | Words chosen for their sound (rhyme/assonance) rather than meaning | "I went to the mall, had a ball, hit the wall, that's all" |
| Perseveration | Repetition of a word, phrase, or idea beyond relevance | Repeating the answer to a previous question for subsequent questions |
| Thought blocking | Sudden interruption of train of thought; patient stops mid-sentence and cannot recall what they were saying | Experienced by patient as thought withdrawal |
| Circumstantiality | Over-inclusive speech that eventually reaches the point (cf. tangentiality which never reaches the point) | Long, meandering answer that does eventually answer the question |
| Poverty of content | Speech is adequate in amount but conveys little information | Vague, empty, repetitive speech |
Pathophysiology of FTD: Disrupted connectivity between Wernicke's area (language comprehension), Broca's area (language production), and the prefrontal cortex (executive control of speech). The prefrontal cortex normally acts as a "filter" — organising thoughts into coherent, goal-directed speech. When this breaks down, thoughts become loosely associated and speech becomes disorganised.
- Unpredictable, non-goal-directed behaviour
- Inappropriate affect (laughing at sad news)
- Poor self-care, unkempt appearance
- Agitation or stupor without clear cause
Catatonia ("kata" = down, "tonos" = tension) — a syndrome of psychomotor disturbance that can occur in schizophrenia, mood disorders, or medical conditions.
| Feature | Description |
|---|---|
| Stupor | Markedly decreased reactivity to environment; reduction/absence of movement |
| Catalepsy / waxy flexibility | Passive positioning of limbs maintained against gravity (like bending a candle) |
| Mutism | Absent or minimal verbal response |
| Negativism | Motiveless resistance to all instructions or attempts to be moved |
| Posturing | Spontaneous maintenance of unusual postures |
| Mannerisms / stereotypies | Odd, purposeful movements (mannerisms) or repetitive, non-purposeful movements (stereotypies) |
| Echolalia | Automatic repetition of another's speech |
| Echopraxia | Automatic imitation of another's movements |
| Catatonic excitement | Excessive, purposeless motor activity not influenced by external stimuli |
Pathophysiology of catatonia: Hypothesised to involve GABAergic dysfunction (hence response to benzodiazepines, which enhance GABA), with additional involvement of dopaminergic, glutamatergic, and potentially autoimmune mechanisms. Always consider anti-NMDA receptor encephalitis as a differential for catatonia in young patients.
- Working memory deficits (PFC dysfunction)
- Attention and concentration impairment
- Processing speed reduced
- Executive function impairment (planning, abstract thinking, cognitive flexibility)
- Verbal learning and memory deficits
These are present before the onset of frank psychosis (in the prodromal period) and are relatively stable over time — they do not fluctuate with positive symptoms. They are the strongest predictor of functional outcome — more so than positive or negative symptoms. Unfortunately, they are also the hardest to treat with current medications.
- Depression — extremely common in schizophrenia (up to 80% experience depressive symptoms at some point); contributes significantly to suicide risk
- Anxiety — often present, especially in paranoid presentations
- Dysphoria / irritability
On Mental State Examination (MSE), you may find:
| MSE Domain | Findings |
|---|---|
| Appearance & Behaviour | Unkempt, poor self-care, psychomotor agitation or retardation, bizarre posturing, stereotypies, decreased eye contact, suspicious/guarded demeanour |
| Speech | Poverty of speech (alogia), disorganised speech (loosening of associations, tangentiality, word salad, neologisms), or normal |
| Mood (subjective) / Affect (objective) | Mood may be described as "empty" or "nothing"; affect is typically flat/blunted (reduced range), or may be incongruent (inappropriate to content — e.g. laughing when discussing death) |
| Thought Form | Formal thought disorder (as above) |
| Thought Content | Delusions (persecutory, referential, grandiose, passivity, thought insertion/withdrawal/broadcasting); suicidal ideation must be assessed |
| Perceptions | Auditory verbal hallucinations (2nd or 3rd person, running commentary, thought echo); less commonly visual, olfactory, tactile |
| Cognition | Impaired attention, concentration, working memory, executive function; orientation usually preserved (cf. delirium where it is impaired) |
| Insight | Typically poor — patient does not believe they are unwell, does not see the need for treatment. Insight exists on a spectrum and fluctuates |
| Judgment | Often impaired |
Distinguishing Schizophrenia from Delirium
Both can present with hallucinations and disorganised behaviour, but:
- Delirium: fluctuating consciousness, impaired orientation, visual hallucinations predominate, acute onset with identifiable medical cause, often in elderly
- Schizophrenia: clear consciousness, orientation usually preserved, auditory hallucinations predominate, insidious onset (usually), typically young adults
| Clinical Feature | Pathophysiological Basis |
|---|---|
| Auditory hallucinations | Spontaneous activation of auditory cortex (STG) + failure of self-monitoring (PFC) → inner speech misattributed as external |
| Persecutory delusions | Aberrant dopamine-mediated salience → neutral stimuli perceived as threatening → delusional explanation constructed |
| Thought insertion/withdrawal/broadcasting | Failure of "efference copy" mechanism — the brain normally tags self-generated thoughts as "mine"; when this tagging fails, thoughts feel alien or externally controlled |
| Flat affect | Mesocortical hypodopaminergia + PFC/temporal atrophy → impaired emotional expression circuitry |
| Avolition | Disrupted reward circuitry (PFC → nucleus accumbens) due to mesocortical dopamine deficit → inability to anticipate reward and initiate goal-directed behaviour |
| Formal thought disorder | Disconnection between language areas (Wernicke's, Broca's) and executive control (PFC) → loss of goal-directed, coherent speech |
| Cognitive deficits | PFC grey matter reduction + white matter disconnection → impaired working memory, executive function, processing speed |
| Catatonia | GABAergic dysfunction in motor circuits; may also involve basal ganglia dopaminergic dysregulation |
| Better Prognosis | Worse Prognosis |
|---|---|
| Female sex | Male sex |
| Late onset | Early onset |
| Acute onset with clear precipitant | Insidious onset |
| Prominent positive symptoms | Prominent negative symptoms |
| Prominent affective symptoms | Absence of affective symptoms |
| Good premorbid adjustment | Poor premorbid adjustment |
| Married / good social support | Single / isolated |
| Family history of mood disorders | Family history of schizophrenia |
| Short DUP (duration of untreated psychosis) | Long DUP |
| No substance abuse | Comorbid substance abuse |
| Good treatment adherence | Poor adherence |
High Yield Summary
Definition: Schizophrenia is a chronic neurodevelopmental psychotic disorder characterised by positive symptoms (hallucinations, delusions), negative symptoms (5 A's), disorganisation, cognitive impairment, motor symptoms, and affective disturbance.
Epidemiology: Lifetime risk ~1%; prevalence of all psychotic disorders ~2–3%; M:F = 1.4:1; onset late adolescence/early adulthood; men earlier onset. HK prevalence 2.5%. Incidence varies with urbanicity and migration.
Aetiology — Stress-Vulnerability Model:
- Genetics (80% heritability): Polygenic (dopamine, glutamate, synaptic, immune genes); 22q11.2 deletion → 20–30× risk; MZ concordance ~50%
- Environment: Prenatal (obstetric complications, winter birth, infections, paternal age) + Proximal (cannabis, urbanicity, migration — social defeat hypothesis)
- Gene × environment interaction
Pathophysiology:
- Dopamine hypothesis: Mesolimbic hyper → positive symptoms; Mesocortical hypo → negative/cognitive symptoms
- Glutamate: NMDA hypofunction → excess glutamate → hyperdopaminergia + neurotoxicity
- GABA: Reduced GAD → disinhibition
- Neuropathology: Reduced neuropil, NO gliosis → neurodevelopmental NOT neurodegenerative
- Structural: Reduced GM (temporal, PFC, thalamus, anterior cingulate), increased ventricles, cortical thinning, white matter disconnectivity
Schneider's First Rank Symptoms (SPECTRA): Somatic passivity, Passivity of action/impulse, Echo of thoughts, Commentary/3rd person AVH, Thought insertion/withdrawal/broadcasting, Referential/delusional perception, Audible thoughts
Negative symptoms (5 A's): Avolition, Alogia, Anhedonia, Asociality, Affective flattening
Course: Premorbid → Prodromal (ARMS/CHR) → First Episode Psychosis → Variable longitudinal course (full recovery / residual deficits / chronic)
Delusional disorder: Non-bizarre, systematised, single-themed delusion ≥1 month; preserved functioning; no/minimal hallucinations or negative symptoms; lifetime risk 0.05–0.1%; median onset 46y
Active Recall - Schizophrenia and Related Disorders (Definition to Clinical Features)
Differential Diagnosis of Schizophrenia and Related Psychotic Disorders
When a patient presents with psychotic symptoms (delusions, hallucinations, disorganised thinking/behaviour), the critical task is NOT to immediately label it "schizophrenia." Psychosis is a syndrome — a final common pathway — and the differential is broad. The hierarchy of psychiatric diagnosis dictates that you must rule out causes from the top of the pyramid (organic → substance → psychotic → mood → anxiety → personality) before settling on a diagnosis lower down [2].
Why does the hierarchy matter? Because treating the higher-order disorder (e.g., delirium from a UTI, or substance-induced psychosis from methamphetamine) often resolves the psychosis entirely. Missing an organic cause and treating with antipsychotics alone is a serious — and potentially lethal — error.
First Principle: Psychosis ≠ Schizophrenia
Psychosis is a syndrome (loss of contact with reality) that can be caused by many disorders. Schizophrenia is just ONE cause. Always exclude organic, substance-related, and mood-related causes first. The hierarchy is: Organic > Substance > Psychotic disorders > Mood disorders > Anxiety > Personality [2].
Before diving into the specific differentials, you need a framework for distinguishing primary psychiatric psychosis from secondary (organic) psychosis [2]:
| Feature | Primary (Psychiatric) Psychosis | Secondary (Organic) Psychosis |
|---|---|---|
| Age of onset | Typically young adult (18–35) | Any age, but consider especially if onset > 40 without prior psychiatric history |
| Consciousness | Clear | Often impaired (fluctuating awareness, disorientation — think delirium) |
| Orientation | Usually preserved | Often impaired |
| Hallucination type | Predominantly auditory (especially auditory verbal hallucinations) | Predominantly visual (visual hallucinations should ALWAYS prompt organic work-up) |
| Cognitive function | Subtle deficits (working memory, executive function) but no gross impairment | May show gross cognitive deficits, delirium, confusion |
| Physical signs | Usually absent | May have focal neurological signs, vital sign abnormalities, pupil changes, etc. |
| Course | Chronic/relapsing | Fluctuating, often acute onset; may improve when underlying cause treated |
| Response to context | Psychotic content often stable | Worsening at night (sundowning), fluctuating |
The differential can be organised into four major categories: (1) Other psychotic (non-affective) disorders, (2) Mood disorders with psychotic features, (3) Other psychiatric disorders, and (4) Secondary (organic/substance-related) causes.
Category 1: Other Non-Affective Psychotic Disorders (Schizophrenia-Spectrum)
Schizophrenia-spectrum includes schizophrenia, schizoaffective disorder, schizotypal personality disorder [1].
| Feature | Detail |
|---|---|
| Core distinction | Same symptom criteria as schizophrenia (Criterion A of DSM-5), BUT total duration is 1–6 months |
| Functional decline | NOT required (cf. schizophrenia requires functional decline) |
| Prognosis | Better than schizophrenia; ~1/3 recover fully, ~2/3 progress to schizophrenia or schizoaffective disorder |
| Why it exists | Acts as a "provisional" diagnosis — you can't diagnose schizophrenia until 6 months have elapsed |
Brief psychotic disorder / acute & transient psychotic disorders (ATPD) [1]:
- Acute onset / complete remission / brief period (1–3 months, depends on criteria) [1]
- Polymorphic features (~cycloid psychosis): rapidly changing clinical pictures, prominent fluctuated mood state, perplexity [1]
- Duration: 1 day – 1 month (DSM-5 brief psychotic disorder); onset ≤2 weeks for ATPD (ICD-10) [2]
- May be precipitated by acute stress (intense stressor or traumatic event) [2]
- Rapid recovery is typical
Why distinguish this from schizophrenia? Prognosis is vastly different. Brief psychotic disorder has excellent prognosis with full return to premorbid functioning. Mislabelling it as schizophrenia carries enormous stigma and may lead to unnecessary long-term antipsychotic treatment.
Schizoaffective: concurrent schizophrenic and mood symptoms are equally prominent (fulfilling a major mood episode e.g. manic or depressive episode) [1]
- Diagnosed when a major mood episode (depressive or manic) occurs concurrently with psychotic symptoms meeting Criterion A of schizophrenia [2]
- The critical DSM-5 requirement: psychosis must exist for ≥2 weeks in the ABSENCE of a major mood episode during the total illness duration [2]
- This is what separates it from a mood disorder with psychotic features (where psychosis occurs ONLY during mood episodes)
- Prognosis is intermediate between schizophrenia (worse) and mood disorders (better)
Why is this distinction so important clinically? Treatment differs. Schizoaffective disorder typically requires BOTH an antipsychotic AND a mood stabiliser (or antidepressant, depending on subtype), whereas a mood disorder with psychotic features may respond to mood treatment plus short-term antipsychotic.
Delusional disorder [1]:
- Systematized, likely single-theme delusion, non-bizarre in nature (classic definition) [1]
- No or non-prominent hallucination [1]
- Minimal negative symptoms, reported of having better functioning [1]
- Over-represented by women and adult-onset [1]
- Relatively rare [1]
- Lifetime risk 0.05–0.1%, median onset 46 years [2]
- Delusion themes: persecutory (commonest), erotomania, jealous, somatic, grandiose [2]
- Behaviour unrelated to the delusion is often normal (encapsulated) [2]
| Feature | Delusional Disorder | Schizophrenia |
|---|---|---|
| Delusions | Non-bizarre, systematised, single-themed | Often bizarre, fragmented, multiple themes |
| Hallucinations | Absent or minimal (related to delusion) | Prominent, especially AVH |
| Negative symptoms | Absent or minimal | Often prominent |
| Functioning | Relatively preserved | Significantly impaired |
| Onset age | Later (median 46y) | Earlier (18–35y) |
- Prevalence: 0.6–4.6%, familially aggregates with schizophrenia [2]
- A pervasive, enduring pattern (trait-like, > 2 years) of social/interpersonal deficits with attenuated psychotic-like features [2]:
- Cognitive distortions ("attenuated delusions"): odd beliefs, ideas of reference, magical thinking, paranoid ideation [2]
- Perceptual distortions ("attenuated hallucinations"): illusions, "sixth sense" [2]
- Odd behaviour ("attenuated disorganisation"): vague/circumstantial speech, eccentric appearance [2]
- Social isolation ("attenuated negative symptoms") [2]
- Never met full criteria for schizophrenia throughout entire life [2]
- Considered personality disorder in DSM-5 but schizophrenia-like disorder in ICD-10; part of the schizophrenia-spectrum [2]
Schizotypal vs Schizoid personality disorder: Schizoid PD has similar social isolation and emotional detachment but NO cognitive/perceptual distortions (no attenuated positive symptoms). Schizotypal has the "quasi-psychotic" features; schizoid is just detached and cold [2].
Category 2: Mood Disorders with Psychotic Features
This is one of the most critical differentials — and one of the most commonly missed.
Manic episode with psychotic symptoms misdiagnosed as schizophrenia [3] — this is a classic pitfall.
Misdiagnosis is especially common — among 600 patients with bipolar disorder, 69% were initially misdiagnosed and most frequently as major depression, followed by anxiety disorders, substance/alcohol use disorder [3]. Correct diagnosis and treatment was delayed by 5–7 years on average [3].
Key distinguishing features between mania with psychosis and schizophrenia [2]:
| Feature | Mania with Psychosis | Schizophrenia |
|---|---|---|
| Mood | Elated, expansive, or irritable mood is primary and dominates the picture | Mood disturbance, if any, is secondary or not concurrent with psychosis |
| Psychosis timing | Psychotic symptoms occur during mood episodes and resolve with mood normalisation | Psychosis occurs outside of prominent mood disturbance |
| Delusion content | Usually mood-congruent (grandiose in mania, nihilistic in depression) | Often mood-incongruent, bizarre, with passivity/thought alienation [2] |
| FTD type | Circumstantiality, tangentiality, flight of ideas (with discernible links) | Loosening of associations, neologisms, thought blocking (links absent) [2] |
| Speech | Pressured, difficult to interrupt [2] | More hesitant/halting [2] |
| Sleep | Markedly decreased need for sleep (feels rested after minimal sleep) [2] | Less prominent sleep disturbance |
| Energy/activity | Markedly increased energy and goal-directed activity [2] | Apart from agitation, may have catatonia or negative symptoms [2] |
| Course | Episodic with inter-episode recovery | Chronic with residual deficits |
Why is this misdiagnosis so consequential? Because treatment with antipsychotics alone (appropriate for schizophrenia) is insufficient for bipolar disorder — the patient needs a mood stabiliser (lithium, valproate). Conversely, treating bipolar depression with antidepressants alone (if misdiagnosed as MDD) can trigger a manic switch and accelerate cycling [3].
- Mood disturbance (depression) dominates the clinical picture [2]
- Psychotic content is often mood-congruent: nihilistic delusions ("I am already dead," "my organs are rotting"), delusions of guilt/worthlessness, persecutory delusions (believe punishment is deserved), auditory hallucinations with derogatory content [2]
- Psychotic symptoms occur only during depressive episodes and resolve when depression remits
- Unlike schizophrenia: no prominent formal thought disorder, no bizarre delusions, no negative symptoms outside of depression
Mood-Congruent vs Mood-Incongruent Psychosis
Mood-congruent: Psychotic content is thematically consistent with the mood state (grandiose delusions in mania, nihilistic delusions in depression). Suggests a mood disorder with psychotic features.
Mood-incongruent: Psychotic content has no logical relationship to the mood (e.g., thought insertion, bizarre persecutory delusions in a depressed patient). Suggests schizophrenia or schizoaffective disorder. However, mood-incongruent psychosis CAN occur in mood disorders — it just makes the diagnosis less certain and suggests worse prognosis.
Category 3: Other Psychiatric Disorders that May Mimic Psychosis
- Some obsessions may resemble delusions due to the oddity of beliefs or intensity of conviction (poor-insight OCD) [2]
- Compulsive behaviours and weak resistance may look like disorganised or bizarre behaviour
- Key distinction: OCD symptoms are ego-dystonic (the patient recognises them as unwanted, intrusive, and distressing) whereas delusions in schizophrenia are ego-syntonic (the patient believes them to be true)
- NB: OC symptoms are also common within schizophrenia — always elicit other psychotic features actively [2]
- Borderline personality disorder (BPD): Can present with transient, stress-related paranoid ideation or dissociative symptoms that resemble psychosis. However, these are brief, occur in the context of interpersonal stress, and the patient has an enduring pattern of affective instability, identity disturbance, and impulsive behaviour [2]
- Paranoid personality disorder: Pervasive distrust and suspiciousness, but beliefs are overvalued ideas rather than fixed delusions. Maintains reality testing.
- Personality disorder with prominent irritability can mimic manic psychosis [3]
- Key: personality disorders are trait-like (enduring, pervasive, stable over years), NOT episodic [2]
Attention deficit and hyperactivity disorder [3]:
- Similarities with mania: decreased attention, difficulty with task completion, increased energy, disinhibited behaviour [2]
- Differences: ADHD should NOT have increased self-esteem, grandiosity, flight of ideas, decreased need for sleep [2]
- Course: ADHD is chronic (trait-like) rather than episodic [2]
- ADHD-like symptoms can also overlap with the cognitive and negative symptom dimensions of schizophrenia (poor concentration, reduced motivation), but ADHD lacks psychotic features
- Flashbacks can be misinterpreted as hallucinations
- Hypervigilance and paranoia may resemble persecutory delusions
- Key distinction: PTSD symptoms are clearly linked to a specific traumatic event, and the "hallucinations" are actually re-experiencing phenomena (vivid reliving of the trauma), not true perceptions without external stimuli in the schizophrenia sense
- Can present with social withdrawal, restricted interests, unusual behaviour, and communication difficulties that superficially resemble negative symptoms and disorganisation
- However: no delusions, no hallucinations; the social difficulties stem from impaired social cognition and restricted interests, not from paranoia or avolition
- DSM-5 allows comorbid diagnosis: if a person with ASD develops prominent delusions or hallucinations for ≥1 month, an additional diagnosis of schizophrenia can be made [2]
Category 4: Secondary (Organic and Substance-Related) Causes
This is the category you must not miss — organic psychosis can be life-threatening if the underlying cause is untreated.
- The great mimicker — delirium can present with vivid hallucinations (typically visual), delusions, disorganised speech, agitation or stupor [2]
- Key distinctions from schizophrenia:
- Fluctuating consciousness and attention (cardinal feature)
- Disorientation (to time first, then place, then person)
- Rapid diurnal changes (sundowning)
- Acute onset with identifiable precipitant
- Usually in elderly or medically unwell patients
- Always rule out delirium before diagnosing a primary psychotic disorder, especially in first presentations, older patients, or medically unwell patients [2]
- Especially Lewy body dementia — characterised by vivid visual hallucinations (often well-formed, detailed images of people or animals), fluctuating cognition, and parkinsonism [2]
- Also: Alzheimer's disease (delusions common in moderate–severe stages), frontotemporal dementia (behavioural variant can mimic negative symptoms and disorganisation)
- Key distinction: Progressive cognitive decline is the primary feature; psychosis is secondary
- Anti-NMDA receptor encephalitis — especially important in young women; presents with psychiatric symptoms (psychosis, agitation, catatonia) followed by seizures, movement disorders, autonomic instability. This is treatable with immunotherapy and is a critical "don't miss" diagnosis
- Temporal lobe epilepsy — can cause ictal and post-ictal psychosis, déjà vu, olfactory/gustatory hallucinations
- Autoimmune/infectious encephalitis, MS, leukodystrophies, cerebral lupus (SLE), head trauma, space-occupying lesions (SOL), stroke, neurodegenerative disorders [2]
- Thyroid disorders (both hyper- and hypothyroidism — "myxoedema madness")
- Parathyroid disorders (hypercalcaemia → psychosis)
- Adrenal disorders (Cushing's disease — cortisol excess; Addisonian crisis)
- Vitamin deficiency: B12 (subacute combined degeneration → psychiatric symptoms), B1 (Wernicke's — but this more commonly causes delirium), B3 (pellagra — the classic "3 D's": dermatitis, diarrhoea, dementia/psychosis)
- Hepatic/uraemic encephalopathy
- Acute intermittent porphyria (classically presents with abdominal pain, neuropsychiatric symptoms, and autonomic dysfunction in young women)
- Wilson's disease (copper accumulation — psychiatric symptoms can precede neurological signs; look for Kayser-Fleischer rings) [2]
- Infections: HIV (direct CNS involvement), neurosyphilis (general paresis of the insane — grandiose delusions classically), Lyme disease [2]
| Substance | Key Features | Why it causes psychosis |
|---|---|---|
| Cannabis (THC) | Paranoia, perceptual disturbance, anxiety; dose-response relationship with schizophrenia risk | THC activates CB1 receptors → increases mesolimbic dopamine release |
| Amphetamines / Methamphetamine | Paranoid delusions, tactile hallucinations (formication), agitation; can closely mimic paranoid schizophrenia | Massive dopamine release in mesolimbic pathway |
| Cocaine | Similar to amphetamines; paranoia, tactile hallucinations | Blocks dopamine reuptake → excess synaptic dopamine |
| Alcohol | Alcoholic hallucinosis (vivid AVH in clear consciousness); delirium tremens (VH, confusion, autonomic instability, seizures) during withdrawal | Complex: GABA withdrawal, glutamate rebound, dopamine dysregulation |
| Hallucinogens (LSD, psilocybin) | Vivid visual hallucinations, synaesthesia, depersonalisation | 5-HT2A receptor agonism |
| Ketamine / PCP | Can produce a full schizophrenia-like syndrome including positive AND negative symptoms | NMDA receptor antagonism → supports glutamate hypothesis of schizophrenia |
| Synthetic cannabinoids ("spice") | Severe psychosis, agitation, may be prolonged | Potent CB1 agonism |
- Neurological drugs: Barbiturates, benzodiazepines (especially during withdrawal), anticholinergics, antidepressants (serotonin syndrome), antiepileptics, antiparkinsonian agents (L-DOPA, dopamine agonists) [2]
- Other medications: Corticosteroids (steroid psychosis — dose-related), antimalarials (mefloquine), digoxin, dextromethorphan [2]
- Toxins: Carbon monoxide, organophosphates, heavy metal poisoning (arsenic, manganese, mercury, thallium) [2]
The hierarchy of psychiatric diagnosis is fundamental [2]:
Why does this hierarchy exist? Treating the higher-order disorder often resolves lower-order symptoms (e.g., treating delirium from a UTI resolves the "psychosis"), but NOT vice versa (giving antipsychotics alone won't fix the UTI). You work from the top down [2].
| Diagnosis | Duration | Hallucination type | Mood | Functioning | Key distinguishing feature |
|---|---|---|---|---|---|
| Schizophrenia | ≥6 months (DSM-5) | Auditory predominant | Secondary, if any | Impaired | Bizarre delusions, FRS, negative symptoms, chronic course |
| Schizophreniform | 1–6 months | Auditory | Variable | May be preserved | Same as schizophrenia but shorter duration |
| Brief psychotic / ATPD | < 1 month | Any | Fluctuating, perplexity | Returns to baseline | Rapid onset, polymorphic, often stress-related, full recovery |
| Schizoaffective | Prolonged | Auditory | Prominent mood episode | Variable | Psychosis ≥2 weeks WITHOUT mood episode |
| Delusional disorder | ≥1 month | Minimal/absent | Relatively normal | Preserved | Single-themed, non-bizarre, encapsulated delusion |
| Mania with psychosis | Episodic | Auditory | Elated/irritable, primary | Impaired during episode | Mood-congruent psychosis, flight of ideas, pressured speech, decreased need for sleep |
| MDD with psychosis | Episodic | Auditory | Depressed, primary | Impaired during episode | Mood-congruent (nihilistic, guilt), psychosis only during depression |
| Delirium | Days–weeks | Visual predominant | Labile | Acutely impaired | Fluctuating consciousness, disorientation, acute onset |
| Substance-induced | Related to use | Variable | Variable | Variable | Temporal relationship to substance use/withdrawal; resolves when substance clears |
High Yield Summary
Approach to psychotic symptoms — always use the diagnostic hierarchy:
- Rule out organic/medical causes first — especially delirium (visual hallucinations, fluctuating consciousness, disorientation), anti-NMDA receptor encephalitis, and metabolic/endocrine conditions
- Rule out substance-induced psychosis — temporal relationship to substance use; urine tox screen; should remit after substance clears
- Distinguish from mood disorders with psychotic features — is psychosis occurring ONLY during mood episodes (mood disorder) or also independently (schizoaffective/schizophrenia)?
- Differentiate among psychotic disorders by duration — brief psychotic disorder ( < 1 month) → schizophreniform (1–6 months) → schizophrenia ( > 6 months)
- Delusional disorder — isolated, non-bizarre, encapsulated delusion; preserved functioning; no/minimal hallucinations or negative symptoms
- Schizotypal PD — attenuated psychotic-like features that are trait-like and enduring; never meets full criteria for schizophrenia
Classic exam pitfalls:
- Manic psychosis misdiagnosed as schizophrenia (look for elevated mood, decreased need for sleep, grandiosity, pressured speech, episodic course)
- Visual hallucinations should prompt organic work-up (delirium, Lewy body dementia, substance-induced)
- Anti-NMDA receptor encephalitis in young women with new-onset psychosis + catatonia + seizures
- Cannabis/methamphetamine-induced psychosis in Hong Kong context
Active Recall - Differential Diagnosis of Schizophrenia and Related Disorders
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (pp. 22) [2] Senior notes: ryanho-psych.md (sections 6.1, 6.2, pp. 123–124, 128, 132–133, 143, 165) [3] Lecture slides: GC 163. I am a superman Bipolar disorder.pdf (pp. 10, 12)
Diagnostic Criteria for Schizophrenia and Related Disorders
Schizophrenia is a clinical diagnosis — there is no blood test, no imaging finding, and no biomarker that confirms it. The diagnosis rests entirely on the clinical picture (history + mental state examination), supplemented by investigations whose purpose is to exclude secondary causes, not to confirm schizophrenia itself. This is a crucial first-principles point to understand everything that follows.
The diagnostic criteria serve as standardised "checklists" that ensure:
- The correct cluster of symptoms is present
- For a sufficient duration (to distinguish from transient psychotic episodes)
- Causing sufficient functional impairment
- Not better explained by mood disorders, substances, or medical conditions
ICD-10 vs DSM-5: Key Differences for Exams
Schizophrenia duration: ICD-10 requires 1 month of symptoms; DSM-5 requires 6 months of disturbance (including prodromal/residual phases, with at least 1 month of active-phase symptoms) [2][4]. This means a patient who has had psychotic symptoms for 2 months could be diagnosed with schizophrenia under ICD-10 but only schizophreniform disorder under DSM-5. ICD-10 lists schizophrenia subtypes (e.g. paranoid, hebephrenic); DSM-5 doesn't [2][4]. Catatonia: not specific to schizophrenia, currently used as a diagnostic specifier in DSM-5 [1].
This is the criteria you must know cold for exams [2]:
| Criterion | Requirement | Explanation |
|---|---|---|
| A. Characteristic symptoms | ≥2 of the following, each present for a significant portion of time during a 1-month period (or less if successfully treated). At least one must be (1), (2), or (3) | This ensures the diagnosis requires a "core psychotic symptom" — you cannot diagnose schizophrenia with only disorganised behaviour and negative symptoms |
| (1) Delusions | ||
| (2) Hallucinations | ||
| (3) Disorganised speech (e.g. frequent derailment or incoherence) | ||
| (4) Grossly disorganised or catatonic behaviour | ||
| (5) Negative symptoms (i.e. diminished emotional expression or avolition) | ||
| B. Functional impairment | Impaired level of functioning in ≥1 domain (work, relationships, self-care) for a significant portion of time since onset. In childhood/adolescence: failure to achieve expected level of functioning | This distinguishes schizophrenia from milder psychotic presentations |
| C. Duration | Continuous signs of disturbance for ≥6 months, which must include ≥1 month of symptoms meeting Criterion A | The 6 months can include prodromal or residual periods with attenuated symptoms (e.g. negative symptoms, odd beliefs). This is what makes DSM-5 stricter than ICD-10 |
| D. Exclusion of schizoaffective and mood disorders | Does NOT meet criteria for schizoaffective disorder, or mood disorder with psychotic features | If mood episodes have occurred, they must be brief relative to the psychotic periods |
| E. Exclusion of substance/medical condition | Not attributable to substance or another medical condition | This is why investigations are essential |
| F. ASD clause | If history of autism spectrum disorder, additional diagnosis of schizophrenia only if prominent delusions or hallucinations are present for ≥1 month | Prevents over-diagnosis in patients whose social withdrawal and odd behaviour are explained by ASD alone [2] |
DSM-5 Course Specifiers [2]:
- First episode: currently in acute episode / partial remission / full remission
- Multiple episodes: currently in acute episode / partial remission / full remission
- Continuous
- Unspecified
- With catatonia (specifier)
Why does DSM-5 require 6 months but ICD-10 only requires 1 month? The 6-month criterion was introduced to improve specificity — it reduces the chance of diagnosing schizophrenia in patients who actually have brief psychotic disorder or schizophreniform disorder (which have better prognoses). However, it sacrifices sensitivity — some true schizophrenia patients will be "underdiagnosed" in the early months. In practice, this rarely matters because treatment starts regardless; the label changes later.
ICD-10 places greater emphasis on Schneider's first-rank symptoms and is structured differently [2]:
Required duration: Symptoms clearly present for most of the time during ≥1 month [2].
The criteria are divided into "major" (first-rank) and "minor" symptoms:
At least 1 "major" symptom from groups (a)–(d), OR symptoms from ≥2 of groups (e)–(h):
| Group | Symptom (Major — First Rank) |
|---|---|
| (a) | Thought echo, thought insertion or withdrawal, thought broadcasting |
| (b) | Delusions of control, influence, or passivity (clearly referred to body/limb movements or specific thoughts, actions, or sensations); delusional perception |
| (c) | Hallucinatory voices giving running commentary, or discussing the patient among themselves, or other types of hallucinatory voices coming from some part of the body |
| (d) | Persistent delusions of other kinds that are culturally inappropriate and completely impossible (bizarre delusions) |
| Group | Symptom (Minor) |
|---|---|
| (e) | Persistent hallucinations in any modality, when accompanied by fleeting/half-formed delusions, persistent overvalued ideas, or occurring every day for weeks/months |
| (f) | Breaks or interpolations in the train of thought → incoherence, irrelevant speech, neologisms |
| (g) | Catatonic behaviour: excitement, posturing, waxy flexibility, negativism, mutism, stupor |
| (h) | Negative symptoms: marked apathy, paucity of speech, blunting/incongruity of emotional responses (must be clear these are not due to depression or neuroleptic medication) |
| (i) | Significant and consistent change in overall quality of personal behaviour (loss of interest, aimlessness, idleness, self-absorbed attitude, social withdrawal) |
ICD-10 Subtypes (still in use though not in DSM-5) [1][2]:
| Subtype | Key Features |
|---|---|
| Paranoid (F20.0) | Prominent positive symptoms — dominated by relatively stable delusions (often control, influence, passivity, persecutory) and hallucinations, with relatively less prominent negative, catatonic, and disorganisation symptoms [1][2] |
| Hebephrenic/Disorganised (F20.1) | Younger age of onset, prominent thought disorder / incongruous affect, poor prognosis [1][2] |
| Catatonic (F20.2) | Constellation of specific motor signs e.g. posturing, waxy flexibility, mutism [1][2] |
| Simple (F20.6) | Lack of positive symptoms, gradual functional decline, prominent negative symptoms [1][2] |
| Undifferentiated (F20.3) | Not conforming to above subtypes [2] |
| Post-schizophrenic depression (F20.4) | Previous schizophrenia with residual symptoms and prominent depression meeting depressive episode criteria [2] |
| Residual (F20.5) | Prominent negative symptoms with prior psychotic episode for ≥1 year [2] |
Subtype classification is no longer included in DSM-5 [1] — because subtypes showed poor diagnostic stability (patients shifted between subtypes over time), low inter-rater reliability, and limited clinical utility for guiding treatment.
3. Diagnostic Criteria for Related Disorders
| Criterion | Requirement |
|---|---|
| A | Meets Criterion A of schizophrenia |
| B | Total duration of episode is ≥1 month but < 6 months |
| Criterion B (functional decline) of schizophrenia is NOT required |
This is essentially a "provisional schizophrenia" — if symptoms persist beyond 6 months, the diagnosis is upgraded to schizophrenia [2].
| DSM-5: Brief Psychotic Disorder | ICD-10: ATPD |
|---|---|
| ≥1 psychotic symptom for ≥1 day but < 1 month | Acute onset ( < 2 weeks) |
| Full return to premorbid functioning | Complete recovery within 2–3 months [2] |
| Specifiers: with/without marked stressor, with peripartum onset | Polymorphic features (~cycloid psychosis): rapidly changing clinical pictures, prominent fluctuated mood state, perplexity [1] |
| Criterion | Requirement | Rationale |
|---|---|---|
| A | Major mood episode (manic or depressive) concurrent with Criterion A of schizophrenia | Schizoaffective: concurrent schizophrenic and mood symptoms are equally prominent (fulfilling a major mood episode) [1] |
| B | Delusions or hallucinations for ≥2 weeks in the absence of a major mood episode (during the total illness) | This is the critical criterion — it proves the psychosis is NOT simply a feature of the mood disorder |
| C | Symptoms meeting criteria for a major mood episode are present for the majority of the total active and residual illness duration | Prevents diagnosing schizoaffective disorder in a patient with schizophrenia who has a brief depressive episode |
| D | Not attributable to substance or medical condition | Standard exclusion |
| Criterion | Requirement |
|---|---|
| A | ≥1 delusion lasting ≥1 month |
| B | Has never met Criterion A of schizophrenia — hallucinations, if present, are not prominent and are related to the delusional theme [2] |
| C | Functioning and behaviour relatively normal apart from the delusion and its ramifications [2] |
| D | If mood episodes have occurred, they have been brief relative to the delusional periods |
| E | Not attributable to substance or medical condition |
| Disorder | Duration Requirement (DSM-5) | Duration Requirement (ICD-10) |
|---|---|---|
| Brief psychotic disorder | 1 day – < 1 month | Acute onset < 2 weeks, recovery within 2–3 months |
| Schizophreniform disorder | ≥1 month – < 6 months | (Not a separate entity in ICD-10; would be diagnosed as schizophrenia if > 1 month) |
| Schizophrenia | ≥6 months total (including ≥1 month Criterion A) | ≥1 month of symptoms |
| Delusional disorder | ≥1 month | ≥3 months |
| Schizoaffective disorder | Total illness duration with mood episode for majority + ≥2 weeks psychosis without mood episode | Simultaneous occurrence for ≥2 weeks |
How to use this algorithm: Work from the top down — this mirrors the diagnostic hierarchy. You systematically exclude organic causes first, then substances, then mood disorders, before concluding it's a primary psychotic disorder. Only then do you differentiate by duration and symptom profile.
6. Investigations in First-Episode Psychosis
Remember: investigations in psychosis are not to confirm schizophrenia but to exclude secondary causes. A first-episode psychosis (FEP) should be treated as "guilty until proven innocent" — assume an organic cause until you've ruled it out.
| Investigation | Purpose | Key Findings / Interpretation |
|---|---|---|
| Full blood count (FBC) | Exclude infection (↑WCC), anaemia, macrocytosis (B12/folate deficiency, alcohol) | Leucocytosis → infection/delirium. MCV > 100 → B12/folate deficiency or alcohol use |
| Renal function (U&E, Cr) | Exclude uraemic encephalopathy; baseline before medication | ↑Urea/Cr → uraemic psychosis. Also needed for medication dosing |
| Liver function tests (LFTs) | Exclude hepatic encephalopathy; baseline before medication (many antipsychotics are hepatically metabolised) | ↑AST/ALT → hepatic cause; also screens for alcohol-related liver disease |
| Thyroid function tests (TFTs) | Exclude thyroid disease — both hyperthyroidism (agitation, psychosis) and hypothyroidism ("myxoedema madness") | ↑TSH + ↓T4 → hypothyroidism; ↓TSH + ↑T4 → hyperthyroidism |
| Fasting glucose / HbA1c | Baseline metabolic screen (critical before starting 2nd-generation antipsychotics which cause metabolic syndrome); exclude hypoglycaemia as cause of altered mental state | Hypoglycaemia → episodic confusion/psychosis. Also establishes baseline for metabolic monitoring on antipsychotics |
| Fasting lipid profile | Baseline metabolic screen before antipsychotics | Establishes baseline; 2nd-generation antipsychotics (especially olanzapine, clozapine) can cause dyslipidaemia |
| Calcium, phosphate | Exclude hypercalcaemia (hyperparathyroidism → psychosis), hypocalcaemia | ↑Ca²⁺ → confusion, psychosis ("bones, stones, groans, and psychiatric moans") |
| B12 and folate | Exclude deficiency — B12 deficiency can present with psychosis, cognitive decline, and neurological signs (subacute combined degeneration) before haematological changes appear [2] | ↓B12 → megaloblastic anaemia + neuropsychiatric symptoms |
| Syphilis serology (VDRL/RPR ± TPHA) | Exclude neurosyphilis — classically presents with grandiose delusions ("general paresis of the insane") [2] | Positive serology → further CSF analysis needed |
| ESR / CRP | Non-specific inflammatory markers; screen for autoimmune/infectious causes [2] | ↑ESR/CRP → suggests underlying inflammatory/infectious process |
| Urine drug screen (UDS) | Critical in every FEP — exclude substance-induced psychosis (cannabis, amphetamines/methamphetamine, cocaine, ketamine, synthetic cannabinoids) [2] | Positive → does not exclude comorbid primary psychotic disorder, but substance must clear before diagnosis can be finalised |
| ECG | Baseline QTc before starting antipsychotics (many prolong QT interval); also screens for cardiac arrhythmia [2] | Prolonged QTc ( > 500ms or increase > 60ms) → high risk of torsades de pointes. Haloperidol, ziprasidone particularly associated with QT prolongation |
| Investigation | When to Consider | Key Findings |
|---|---|---|
| CT / MRI brain | First-episode psychosis (to exclude structural lesion); atypical presentations; late onset ( > 40y); focal neurological signs; head injury [2] | Space-occupying lesion, stroke, demyelination, enlarged ventricles (can be seen in schizophrenia but is not diagnostic). In established schizophrenia: reduced GM volume, increased ventricular volume (research finding, not used diagnostically) |
| EEG | Suspected epilepsy (temporal lobe epilepsy can present with psychosis); catatonia; suspected non-convulsive status epilepticus [2] | Epileptiform discharges → ictal/post-ictal psychosis. Diffuse slowing → encephalopathy/delirium |
| CSF analysis | Suspected encephalitis (viral, autoimmune — e.g. anti-NMDA receptor encephalitis); neurosyphilis | ↑WCC/protein → infection/inflammation. Anti-NMDA receptor antibodies → autoimmune encephalitis. Positive VDRL in CSF → neurosyphilis |
| HIV serology | Risk factors present; mandatory consideration in FEP in many settings | HIV → CNS involvement can cause psychosis directly, or via opportunistic infections |
| Autoimmune screen (ANA, anti-dsDNA, complement) | Suspected SLE (cerebral lupus can present with psychosis), especially in young women with multi-system involvement | Positive ANA + anti-dsDNA + low complement → lupus |
| Anti-NMDA receptor antibodies (serum + CSF) | Young patient (especially female) with new-onset psychosis + seizures + movement disorder + autonomic instability + catatonia | Positive → anti-NMDA receptor encephalitis — a treatable, potentially reversible cause of psychosis |
| Ceruloplasmin, serum copper, 24h urine copper, slit-lamp exam | Young patient ( < 40y) with psychosis + movement disorder + liver disease | ↓Ceruloplasmin, ↑urine copper, Kayser-Fleischer rings → Wilson's disease |
| Urine porphyrins / porphobilinogen | Episodic psychosis with abdominal pain + neuropathy, especially young women | ↑Porphobilinogen → acute intermittent porphyria |
| Serum cortisol / dexamethasone suppression test | Cushingoid features | ↑Cortisol, non-suppression → Cushing's disease |
| Heavy metal screen | Occupational exposure; specific clinical suspicion | Positive → arsenic, manganese, mercury, thallium poisoning [2] |
Cognitive impairment is a core feature in schizophrenia [1]:
- Key determinant of functional outcome [1]
- Unmet therapeutic need, not responsive to antipsychotic treatment [1]
- Generalised cognitive impairment encompassing multiple cognitive domains: sustained attention, executive functions (planning, set-shifting, inhibition control), working memory, verbal and visual memory (immediate registration and recall), processing speed [1]
- In general, 1–2 standard deviations below normal healthy controls [1]
- Healthy first-degree relatives of patients also demonstrate deficits (albeit less severe) in cognition [1]
- Impairment in social cognition observed including deficits in Theory of Mind (ToM), emotion recognition etc. [1]
Formal neuropsychological testing (e.g. MATRICS Consensus Cognitive Battery) can be used to quantify deficits and guide cognitive remediation therapy, though this is typically done after acute stabilisation rather than during the acute diagnostic work-up.
This is critically important given the metabolic morbidity associated with schizophrenia and its treatment:
| Parameter | Why | Frequency of Monitoring |
|---|---|---|
| Weight, BMI, waist circumference | Baseline before antipsychotics (especially 2nd-generation) → metabolic syndrome risk | At baseline, then monthly for 3 months, then 3-monthly |
| Blood pressure | Antipsychotics can cause orthostatic hypotension (α1 blockade); metabolic syndrome screening | At baseline and regularly |
| Fasting glucose + lipids | Metabolic syndrome monitoring | At baseline, 3 months, then annually |
| Prolactin | 2nd-generation antipsychotics (especially risperidone, paliperidone, amisulpride) cause hyperprolactinaemia → galactorrhoea, amenorrhoea, osteoporosis, sexual dysfunction | If symptoms develop; some guidelines recommend baseline |
| Investigation | Typical Finding in Schizophrenia |
|---|---|
| CT/MRI brain | May show enlarged ventricles, reduced cortical GM volume — but these are non-specific and not diagnostic. Many patients have normal scans. These are research-level findings. |
| EEG | Usually normal (helps distinguish from epilepsy/delirium where it's abnormal) |
| Blood tests | All normal (if secondary causes excluded) — this is expected since schizophrenia is diagnosed clinically |
| CSF | Normal (helps exclude encephalitis) |
The investigation findings in schizophrenia are defined by their negativity — the absence of organic findings IS the finding. This is why schizophrenia remains a clinical diagnosis of exclusion.
While not "investigations" per se, structured tools help standardise assessment:
| Tool | Purpose |
|---|---|
| PANSS (Positive and Negative Syndrome Scale) | Quantifies severity of positive symptoms (7 items), negative symptoms (7 items), and general psychopathology (16 items). Used in clinical trials and treatment monitoring |
| BPRS (Brief Psychiatric Rating Scale) | Shorter, more practical measure of overall symptom severity |
| CGI (Clinical Global Impression) | Global severity and improvement rating |
| GAF (Global Assessment of Functioning) | Rates overall social, occupational, and psychological functioning (0–100) |
| CAARMS / SIPS | Specifically for assessing at-risk mental state (ARMS) / clinical high-risk (CHR) for psychosis |
| Calgary Depression Scale for Schizophrenia | Assesses depression specifically in schizophrenia (distinguishes depressive symptoms from negative symptoms) |
Practical Exam Tip: What to Mention When Asked 'Investigations for Schizophrenia'
Structure your answer as:
- Exclude organic causes: FBC, U&E, LFTs, TFTs, Ca²⁺, B12/folate, glucose, syphilis serology, ESR/CRP
- Exclude substance-related causes: Urine drug screen
- Baseline before treatment: ECG (QTc), fasting glucose, fasting lipids, weight/BMI, prolactin
- Additional if clinically indicated: CT/MRI brain (FEP, atypical presentation, late onset), EEG (if seizures/catatonia), CSF (if encephalitis suspected), HIV, autoimmune screen, anti-NMDA receptor antibodies
- Functional assessment: Neuropsychological testing, structured rating scales (PANSS)
High Yield Summary
Diagnosis of schizophrenia is CLINICAL — investigations exclude secondary causes, not confirm schizophrenia.
DSM-5 Criteria (memorise):
- A: ≥2 of delusions, hallucinations, disorganised speech, disorganised/catatonic behaviour, negative symptoms; at least one must be delusions, hallucinations, or disorganised speech; present for significant portion of ≥1 month
- B: Functional decline
- C: ≥6 months total duration (including prodromal/residual)
- D: Not schizoaffective or mood disorder with psychotic features
- E: Not substance/medical condition
- F: ASD clause
Key ICD-10 vs DSM-5 difference: ICD-10 requires 1 month; DSM-5 requires 6 months. ICD-10 retains subtypes; DSM-5 uses course specifiers.
Duration continuum: Brief psychotic disorder ( < 1 month) → Schizophreniform (1–6 months) → Schizophrenia ( ≥ 6 months)
Schizoaffective key criterion: Psychosis for ≥2 weeks WITHOUT mood episode
Mandatory FEP investigations: FBC, U&E, LFTs, TFTs, Ca²⁺, B12/folate, glucose, lipids, syphilis serology, ESR/CRP, urine drug screen, ECG. CT/MRI brain recommended for all FEP.
Cognitive impairment: Core feature, 1–2 SD below normal, strongest predictor of functional outcome, NOT responsive to antipsychotics — an unmet therapeutic need.
Active Recall - Diagnostic Criteria, Algorithm, and Investigations
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (pp. 7, 8, 9, 11, 22) [2] Senior notes: ryanho-psych.md (sections 6.1, 6.2, pp. 4, 33, 124–125, 128–135) [4] Senior notes: ryanho-psych.md (section on ICD-10 vs DSM-5 comparison, pp. 6–7)
Management of Schizophrenia and Related Disorders
Managing schizophrenia is a long-game — this is not an acute illness you treat and cure. It is a chronic, relapsing-remitting condition that requires a biopsychosocial approach across multiple phases. Think of it in three time horizons:
- Acute phase — stabilise the psychosis (primarily pharmacological)
- Maintenance phase — prevent relapse (pharmacological + psychosocial)
- Long-term recovery — maximise functioning, independence, and quality of life (primarily psychosocial + ongoing medication)
The management also depends on the stage of illness: first-episode psychosis (FEP) is approached differently from chronic relapsing schizophrenia, which is again different from treatment-resistant schizophrenia.
- Hospitalisation necessary for first-episode psychosis or severe relapses [2]
- Advantages: thorough assessment (including excluding organic causes), better medication compliance (supervised administration), relief for family, management of risk (self-harm, harm to others), and establishment of therapeutic rapport [2]
- May be involuntary under the Mental Health Ordinance (Cap. 136) in Hong Kong if criteria met (mental disorder + risk to self/others + refuses voluntary admission)
- Home/community treatment possible for less severe episodes and the maintenance phase [2]
- Advantages: avoids institutionalisation, maintains social networks, less stigma
- Requires good community support, adherent patient, and low-risk presentation
2. Pharmacological Treatment
Antipsychotic medication as the mainstay treatment [1]
Effective in treating positive psychotic symptoms [1]
> 80% of patients with first-episode psychosis respond to antipsychotic treatment in first psychotic episode [1]
Mechanism of action: D2 receptor antagonist (striatum) [1]
Why D2 blockade works: In schizophrenia, the mesolimbic pathway is hyperdopaminergic. D2 receptor antagonism in the mesolimbic system reduces this excess dopaminergic signalling, thereby reducing the aberrant salience that drives delusions and hallucinations. The drug only needs to occupy 70–80% of striatal D2 receptors to be clinically effective [2].
Excessive D2 blockade (> 70–80% of striatal D2 receptors) → motor side-effects [1]
Why does excessive blockade cause EPS? Beyond the 70–80% threshold needed for therapeutic effect, additional D2 blockade in the nigrostriatal pathway tips the balance of the direct/indirect motor pathways, causing parkinsonism, dystonia, and akathisia. This is the therapeutic window concept — enough blockade to treat psychosis, not so much as to cause EPS.
The traditional classification divides antipsychotics into first-generation (FGA, "typical") and second-generation (SGA, "atypical"), though newer evidence suggests this classification has limited clinical significance — drugs should be considered individually based on their side effect profiles [2].
| Feature | First-Generation Antipsychotics (FGA / Typical) | Second-Generation Antipsychotics (SGA / Atypical) |
|---|---|---|
| Examples | Haloperidol, chlorpromazine, trifluoperazine, flupentixol, zuclopenthixol | Risperidone, olanzapine, quetiapine, aripiprazole, amisulpride, clozapine, paliperidone, lurasidone, asenapine |
| Primary MoA | D2 receptor antagonism (primarily) | D2 antagonism + 5-HT2A antagonism (+ variable effects on other receptors) |
| Positive symptoms | Effective | Equally effective (with exception of clozapine which is superior) |
| Negative symptoms | Limited efficacy | May be slightly better (via 5-HT2A antagonism → increased dopamine release in prefrontal cortex) |
| Main side effects | EPS (high), hyperprolactinaemia (high) | Metabolic syndrome (weight gain, diabetes, dyslipidaemia), sedation |
Why do SGAs cause less EPS? The 5-HT2A antagonism of SGAs disinhibits dopamine release specifically in the nigrostriatal pathway, partially counteracting the D2 blockade there. This "restores" some dopaminergic tone in the motor pathway, reducing EPS risk. However, this comes at the cost of metabolic effects from histamine H1, muscarinic, and serotonin receptor interactions.
Side effects of antipsychotics are explained by their receptor binding profiles beyond D2:
| Receptor Blocked | Side Effects | Mnemonic | Worst Offenders |
|---|---|---|---|
| D2 (nigrostriatal) | EPS: parkinsonism, acute dystonia, akathisia, tardive dyskinesia | Haloperidol, FGAs generally, risperidone | |
| D2 (tuberoinfundibular) | Hyperprolactinaemia → galactorrhoea, amenorrhoea, sexual dysfunction, osteoporosis | Amisulpride, risperidone/paliperidone, sulpiride | |
| H1 (histamine) | Sedation, weight gain | H = Histamine | Chlorpromazine, olanzapine, quetiapine, clozapine |
| α1 (adrenergic) | Postural hypotension, dizziness, reflex tachycardia | A = Alpha | Chlorpromazine, quetiapine, clozapine |
| M1 (muscarinic) | Dry mouth, blurred vision, constipation, urinary retention, cognitive impairment | M = Muscarinic | Clozapine, olanzapine, chlorpromazine |
"Anti-HAM" = anti-Histaminergic + anti-Adrenergic (α1) + anti-Muscarinic effects. This framework lets you predict side effects from receptor profiles [2].
| Side Effect | Highest Risk | Lowest Risk |
|---|---|---|
| EPS | Haloperidol, FGAs | Clozapine (0), quetiapine (0), aripiprazole (+) |
| Prolactin elevation | Amisulpride (+++), risperidone/paliperidone (+++) | Clozapine (0), aripiprazole (0), quetiapine (0) |
| Weight gain | Clozapine (+++), olanzapine (+++) | Aripiprazole (0), lurasidone (0), amisulpride (+) |
| QTc prolongation | Amisulpride, haloperidol, ziprasidone | Aripiprazole, lurasidone |
| Sedation | Chlorpromazine, quetiapine, olanzapine, clozapine | Amisulpride, aripiprazole, paliperidone |
Aripiprazole — The Odd One Out
Aripiprazole is unique in that it is a partial dopamine agonist (not a pure antagonist). It acts as a "dopamine stabiliser" — in hyperdopaminergic states (mesolimbic pathway), it acts as a functional antagonist (reducing activity); in hypodopaminergic states (mesocortical), it acts as a partial agonist (boosting activity). This gives it a favourable side effect profile: minimal D2 blockade-related effects (low EPS, no prolactin elevation, no metabolic syndrome). However, its pro-dopaminergic effects can cause insomnia, nausea, vomiting, and restlessness/agitation [2].
| Formulation | When to Use | Key Points |
|---|---|---|
| Oral (tablets/liquid) | Standard — first-line for most patients | Most flexible for dose titration |
| Rapid-acting IM injection | Acute agitation/aggression requiring rapid tranquillisation | Haloperidol IM, olanzapine IM, aripiprazole IM. Onset within 15–30 minutes |
| Long-acting injectable (LAI / Depot) | Maintenance phase in patients with poor adherence | Paliperidone palmitate (monthly/3-monthly), aripiprazole LAI (monthly), flupentixol decanoate, zuclopenthixol decanoate. Ensures continuous therapeutic levels. Should be avoided in elderly and those at risk of overdose/drug interactions due to difficulty in reversal [2] |
Why use depot injections? Non-adherence is the major risk factor for relapse — up to 52% of patients are non-adherent [2]. Depot formulations guarantee medication delivery and remove the daily decision to take or skip a pill. Studies show depots reduce relapse and rehospitalisation rates.
High risk of relapse [1]
Major risk factor of relapse: non-adherence to medication [1]
At least 1–2 year maintenance antipsychotic treatment following positive symptom remission is recommended for first-episode psychosis (also depends on individual case) [1]
| Episode | Recommended Duration | Rationale |
|---|---|---|
| First episode | ≥1–2 years after symptom remission | Even with treatment, 80–98% relapse if medication discontinued prematurely. Must balance risk of relapse vs long-term side effects [2] |
| Second episode / multiple relapses | ≥5 years or indefinite | Each relapse carries risk of incomplete recovery and progressive functional decline |
| Treatment-resistant / chronic | Indefinite (lifelong) | Stopping medication almost always leads to relapse |
Why such long maintenance? The neurobiology doesn't "reset" after a psychotic episode. The underlying dopamine dysregulation persists. Antipsychotics suppress psychosis but don't cure the underlying vulnerability. Stopping medication removes the suppressive effect, and the mesolimbic hyperdopaminergia re-emerges → relapse. Additionally, each relapse may cause further neurotoxic damage and progressive structural brain changes.
Treatment-resistant schizophrenia [1]:
- Persistent, prominent positive psychotic symptoms despite at least 2 trials of different types of antipsychotic medications with adequate dose and adequate duration (6–8 weeks) [1]
- Indication for clozapine initiation [1]
Clozapine is the gold standard for TRS — it is the only drug proven to be superior in treatment-resistant patients [2].
| Property | Detail |
|---|---|
| Prevalence of TRS | 10–30% of schizophrenia patients [2] |
| Definition | Persistent, prominent positive symptoms despite ≥2 adequate antipsychotic trials (≥1 atypical), each at maximally tolerated dose for ≥6–8 weeks [2] |
| Drug of choice | Clozapine [2] |
| Response rate | ~30% of TRS patients respond to clozapine [2] |
| Additional benefits | Reduced suicidality (only antipsychotic with this indication), reduced aggression, benefit in comorbid substance abuse [2] |
| EPS profile | 0 — virtually no EPS (minimal D2 affinity) [2] |
| Prolactin | 0 — no prolactin elevation [2] |
Clozapine Side Effects — The Trade-off:
| Side Effect | Detail | Mechanism |
|---|---|---|
| Agranulocytosis | Potentially life-threatening; highest risk in first 18 weeks | Idiosyncratic immune-mediated destruction of granulocytes |
| Weight gain | Severe (+++) | H1 + 5-HT2C antagonism → appetite stimulation |
| Metabolic syndrome | Diabetes, dyslipidaemia | Insulin resistance (mechanism incompletely understood) |
| Sedation | Severe | H1 antagonism |
| Constipation | Can be severe → functional intestinal obstruction (ileus) — potentially fatal | Muscarinic (M1) antagonism → reduced gut motility |
| Seizures | Dose-related; risk increases above 600mg/day | Lowered seizure threshold |
| Myocarditis / cardiomyopathy | Rare but potentially fatal; highest risk in first months | Likely immune-mediated |
| Sialorrhoea (hypersalivation) | Paradoxical — despite being antimuscarinic. Very common | M4 muscarinic agonism (partial agonist at this subtype) |
| Postural hypotension | Significant, especially on initiation | α1 antagonism |
| Pulmonary embolism | Increased risk | Multifactorial (sedation, weight gain, immobility, coagulation effects) |
| Hepatotoxicity / pancreatitis | Rare | Idiosyncratic |
Clozapine Monitoring:
| Monitoring | Schedule | Rationale |
|---|---|---|
| Neutrophil count | Weekly × 18 weeks → Fortnightly until 1 year → Monthly thereafter until end of treatment [2] | To detect agranulocytosis early; treatment must be stopped immediately if neutrophils drop below threshold (< 1.5 × 10⁹/L) |
| Metabolic parameters | Fasting glucose, lipids, weight, BP — regularly | High metabolic risk |
| ECG/Troponin/CRP | Baseline and if symptoms suggest myocarditis | Myocarditis screening |
| Clozapine plasma levels | If poor response, suspected non-adherence, or dose adjustment | Therapeutic range: 0.35–0.5 mg/L; toxic > 1.0 mg/L |
Clozapine Contraindications [2]:
- Neutropenia (absolute)
- Cardiac disease (myocarditis, cardiomyopathy)
- Uncontrolled seizure disorder (relative)
- Severe hepatic impairment (relative)
- Paralytic ileus (relative)
If Clozapine Fails — little consensus on best treatment [2]:
- Add another antipsychotic to clozapine (e.g. amisulpride, aripiprazole)
- ECT augmentation
- Lamotrigine augmentation (evidence for reducing positive symptoms when added to clozapine)
- Benzodiazepines: For acute behavioural disturbances, aggression, agitation, insomnia. Used as short-term adjunct, NOT as standalone treatment for psychosis [2]
- Antidepressants/lithium: For augmentation in treatment-resistant cases (evidence limited), especially when there are significant affective symptoms (e.g. schizoaffective disorder, post-schizophrenia depression) [2]
Non-Adherence: The Biggest Treatment Challenge
Non-compliance is very common (up to 52%) [2]. Risk factors include poor insight, negative attitude to medications, side effects, substance abuse, and lack of social support. Strategies to improve adherence include: depot/LAI formulations, compliance therapy (motivational interviewing), psychoeducation, simplification of regimen, management of side effects, and family involvement.
3. Non-Pharmacological Treatment
Non-pharmacological treatments — usually as an adjunct to medications, aiming to [1][2]:
- Increase interpersonal and social functioning, especially promotion of independent living in community
- Attenuate symptomatic severity and associated comorbidities
- Improve treatment compliance
Cognitive-behavioural therapy (CBT) [1]:
- Residual positive psychotic symptoms (e.g. residual AH) [1]
- Comorbid depressive and anxiety symptoms [1]
| Aspect | Detail |
|---|---|
| Rationale | Positive symptoms may be amenable to structured reasoning and behavioural modification [2] |
| How it works | Breaking thought-behaviour patterns underpinning psychotic symptoms. E.g.: delusional ideas traced back to origin with alternative explanations explored; challenging beliefs about omnipotence and origin of auditory hallucinations [2] |
| Evidence | Effective for residual positive symptoms (especially persistent auditory hallucinations that don't fully respond to medication) and comorbid depression/anxiety [2] |
| Timing | Usually after acute stabilisation; not during florid psychosis |
| Intervention | Purpose | Mechanism / Details |
|---|---|---|
| Treatment compliance therapy [1] | Improve medication adherence | Use of motivational interviewing to explore ambivalence about treatment; address beliefs about illness and medication |
| Cognitive remediation [1] | Reduce cognitive decline and improve daily functioning | Mental exercises/training targeting attention, memory, executive function. Cognitive impairment is an unmet therapeutic need, not responsive to antipsychotic treatment — hence the need for non-pharmacological approaches [1] |
| Occupational rehabilitation / vocational support & training / social skills training [1] | Promote independent living and employment | Supported employment programmes, sheltered workshops, skills training in activities of daily living |
| Community case-management approach [1] | Coordinate care across multiple providers | Assigned case manager provides continuity, monitors symptoms, coordinates services |
| Family intervention (expressed-emotions / EE, caregiver stress & burden, psychoeducation, support) [1] | Reduce relapse by lowering EE; reduce caregiver burden | Family therapy to reduce critical, hostile, emotionally over-involved attitudes (high EE > 35h/week increases relapse risk [2]). Psychoeducation about illness. Support groups |
This is a major focus for mental health service development in the past 20 years [2]:
| Aspect | Detail |
|---|---|
| Rationale | Increased duration of untreated psychosis (DUP) predicts poor outcome (postulated that active psychosis is neurotoxic and delayed treatment leads to irreversible neurological deterioration [2]); phase-specific intervention allows optimal treatment in the critical period (3–5 years after illness onset) [2] |
| Evidence | Benefit demonstrated over standard care in both overseas and local research [2] |
| Local programme | Early Assessment Service for Young people with psychosis (EASY) [2] |
| EASY eligibility | First-episode psychosis at 15–64 years old [2] |
| EASY duration | Covers first 3 years of psychosis, then transferred to general care [2] |
| EASY components | Intensive follow-up with more allied health support and assignment of case managers [2] |
| EASY outcomes | Reduced suicide and hospitalisation rates, improved functioning and symptom outcomes, reduced default rate [2] |
Why is early intervention so important? The "critical period" hypothesis proposes that the first few years after psychosis onset represent a window of neuroplasticity where treatment has maximal impact. Longer DUP is associated with reduced grey matter volume, worse cognitive function, and poorer treatment response. Early detection and intensive treatment during this window can alter the long-term trajectory of illness.
ECT for catatonia / treatment-resistant schizophrenia [1]
| Aspect | Detail |
|---|---|
| Status in schizophrenia | NOT commonly used as first-line; reserved for specific indications [2] |
| Indications | Catatonia (life-threatening, treatment-resistant to benzodiazepines); severe comorbid depression; treatment-resistant cases (especially augmentation with clozapine) [2] |
| Mechanism | Unknown, but hypothesised to involve neuroendocrine effects (increased ACTH, PRL, endorphins), neurotrophic signalling (increased BDNF → neurogenesis), increased monoamine release, and changes in brain connectivity [2] |
| Administration | 6–12 treatments, 2–3 per week; short-acting GA + muscle relaxant; electrodes applied to scalp; electric pulse induces generalised tonic-clonic seizure lasting ≥15 seconds [2] |
| Electrode placement | Bilateral (more effective but more cognitive side effects) vs unilateral (less cognitive impairment; if used, contralateral to dominant hemisphere) [2] |
| Side effects | Acute confusion, anterograde/retrograde amnesia (generally short-lived, lasting days); headache, nausea, muscle pain [2] |
| Mortality | 2–4 per 100,000 (~comparable to minor surgery under GA); usually from cardiopulmonary events [2] |
| Contraindications | No absolute contraindications. Relative: recent MI, heart failure, IHD; raised ICP; risk of ICH (HTN, recent stroke); poor anaesthetic risk [2] |
| Aspect | Detail |
|---|---|
| Course | Highly heterogeneous; usually chronic and relapsing-remitting [2] |
| Outcomes | ~30% treatment-resistant; ~20% achieve sustained remission; ~10% die by suicide; > 50% have poor long-term outcome [2] |
Poor Prognostic Factors [2]:
| Patient Factors | Disease Factors | Other Factors |
|---|---|---|
| Poor premorbid adjustment | Insidious onset, not related to stress | High EE of caregivers |
| Male gender | Prolonged DUP | Comorbid substance abuse |
| Single | Prominent negative and cognitive symptoms | Poor treatment adherence |
| Family history of schizophrenia | Hebephrenic subtype | |
| Prominent affective symptoms (debatable — some sources suggest affective symptoms indicate better prognosis) | ||
| Poor initial treatment response | ||
| Poor insight |
Choosing an Antipsychotic — Practical Approach
There is no single "best" antipsychotic (apart from clozapine for TRS). Choice is guided by side effect profile matched to patient characteristics:
| Patient Factor | Preferred Drug | Drugs to Avoid | Rationale |
|---|---|---|---|
| Obese / metabolic syndrome | Aripiprazole, lurasidone, amisulpride | Olanzapine, clozapine | Weight-neutral options |
| Prolactin-sensitive (young woman, concerns about fertility/osteoporosis) | Aripiprazole, quetiapine | Risperidone, amisulpride, paliperidone | Minimal prolactin elevation |
| Elderly / falls risk | Lower-dose risperidone, aripiprazole | Chlorpromazine, clozapine, quetiapine | Avoid postural hypotension (α1), sedation |
| Cardiac history / QT prolongation | Aripiprazole, lurasidone | Amisulpride, haloperidol, ziprasidone | Lowest QTc risk |
| Poor adherence | Depot/LAI (paliperidone palmitate, aripiprazole LAI) | Any oral if non-adherent | Ensures medication delivery |
| Agitation / insomnia | Quetiapine, olanzapine (sedating) | Aripiprazole (can worsen insomnia) | Use sedation therapeutically |
| Treatment-resistant | Clozapine (only proven option) | Any other agent (by definition, failed 2 trials) | Superior efficacy in TRS |
High Yield Summary
Pharmacological Treatment:
- Antipsychotics are the mainstay; D2 receptor antagonism in the mesolimbic pathway reduces positive symptoms
-
80% of FEP patients respond; 70–80% D2 occupancy needed; excessive blockade → EPS
- Maintenance: ≥1–2 years after FEP; non-adherence is the major relapse risk factor → consider depot formulations
- TRS definition: persistent positive symptoms despite 2 adequate antipsychotic trials (≥1 atypical, each 6–8 weeks, adequate dose)
- Clozapine is the ONLY drug with proven superiority in TRS (~30% response rate); also reduces suicidality and aggression
- Clozapine monitoring: neutrophil count weekly × 18 weeks → fortnightly to 1 year → monthly thereafter
- Clozapine serious side effects: agranulocytosis, metabolic syndrome, seizures, myocarditis, constipation/ileus, PE
- If clozapine fails: add another antipsychotic, ECT augmentation, or lamotrigine augmentation
Non-Pharmacological Treatment:
- CBT for residual positive symptoms and comorbid depression/anxiety
- Family therapy to reduce expressed emotions and caregiver burden
- Cognitive remediation for cognitive impairment (unmet therapeutic need — not responsive to antipsychotics)
- Compliance therapy, vocational rehabilitation, social skills training, community case management
- Early intervention (EASY in HK): intensive support for first 3 years of psychosis → reduced suicide, hospitalisation, and default rates
- ECT: reserved for catatonia, severe comorbid depression, and treatment-resistant cases
Prognosis: Chronic, heterogeneous; ~30% TRS, ~20% sustained remission, ~10% suicide, > 50% poor outcome. Poor prognostic factors include male sex, early onset, insidious onset, prolonged DUP, prominent negative symptoms, poor premorbid adjustment, substance abuse, and high EE.
Active Recall - Management of Schizophrenia
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (pp. 23, 24) [2] Senior notes: ryanho-psych.md (sections 6.2C, 3.1.2, 3.2, 3.3, pp. 45, 65–71, 135–138)
Complications of Schizophrenia and Related Disorders
Complications of schizophrenia can be broadly divided into those arising from the disease itself, those arising from its treatment (iatrogenic), and those arising from the interaction between disease, treatment, and social context. Understanding these complications from first principles — connecting each back to pathophysiology or pharmacology — is essential.
1. Complications of the Disease Itself
Suicide is the single largest cause of premature death in schizophrenia [1]
| Aspect | Detail |
|---|---|
| Lifetime suicide risk | 5.6% (based on first-episode cohorts), 4.9% (from all studies) [1] |
| When is risk highest? | Risk is highest in the early stage of psychotic disorders. Rate is highest in the first year after presentation of FEP (first-episode psychosis) [1] |
| Relative risk | Suicide risk of psychotic patients is 12 times more than expected from general population [1] |
| Key predictor | Depressed mood, one of the strongest predictor of suicide, is frequently observed in the early stage of illness [1] |
Why is the first year after FEP the highest risk period? Several factors converge: (1) the patient is often an intelligent young person who develops insight into the devastating nature of their diagnosis — this "insight–despair paradox" is a powerful driver of hopelessness; (2) depressive symptoms are extremely common in early psychosis; (3) command auditory hallucinations may instruct self-harm; (4) the transition from acute treatment to community care is a vulnerable period with potential loss of support [2].
Additional suicide risk factors specific to schizophrenia:
- Young age, male sex
- Good premorbid functioning (more to lose → greater perceived loss)
- High education level
- Early illness course (especially first 1–5 years)
- Comorbid depression (present in ~25% — post-schizophrenia depression [2])
- Comorbid substance abuse
- Command hallucinations
- Previous suicide attempts
- Recent hospital discharge
- Social isolation, loss of role/employment
- Poor adherence → relapse → crisis
The Insight–Despair Paradox
Counterintuitively, better insight into the illness is associated with higher suicide risk in schizophrenia. This is the opposite of what you might expect. The patient who recognises they have a chronic psychotic illness, who understands the implications for their career, relationships, and independence, may experience profound hopelessness. This is why recovery-oriented approaches and hope-instilling therapeutic relationships are so important alongside medical treatment.
Excess mortality in schizophrenia patients [1]:
- Schizophrenia reduces an affected individual's lifespan by on average 10–15 years [1]
- All-cause standardised mortality ratio (SMR): 2 to 3 [1]
- SMR of schizophrenia: 2.5, shortened life expectancy: 8–10 years in Hong Kong (Yung et al. 2021) [1]
- Elevated both in suicide and natural deaths [1]
- Increased risk of premature deaths related to a wide range of physical illnesses [1]
Possible reasons for elevated rate of natural deaths [1]:
| Reason | Mechanism | Consequence |
|---|---|---|
| Lifestyle (sedentary lifestyle, lack of exercise, poor nutrition) [1] | Negative symptoms (avolition, apathy) → reduced motivation for exercise and self-care; cognitive impairment → difficulty planning meals; poverty → poor dietary choices | Obesity, cardiovascular disease, type 2 diabetes |
| Cigarette smoking [1] | Extremely prevalent in schizophrenia (~60–80% vs ~20% general population). Why? Nicotine partially normalises sensory gating deficits (P50 suppression) and provides transient cognitive enhancement; may also reduce antipsychotic side effects (EPS) via nicotinic receptor stimulation. It is essentially a form of "self-medication" | Lung cancer, COPD, cardiovascular disease |
| Substance or alcohol abuse [1] | Schizophrenia: 30% abuse alcohol [5]. Alcohol may decrease feeling of isolation and temporarily reduce symptoms of anxiety/depression/insomnia — but increases psychotic symptoms and mood swings, causes disruptive behaviour, suicide, treatment non-compliance, drug abuse, poor clinical outcome [5]. Also: drug accumulation due to hepatic damage [5] | Liver disease, pancreatitis, cardiomyopathy, infections, worsened psychosis |
| Metabolic syndrome (obesity, DM, hyperlipidaemia etc.) [1] | Both from disease-inherent metabolic dysregulation AND iatrogenic from second-generation antipsychotics (see Section 2 below) | Cardiovascular disease — the leading cause of death in schizophrenia |
| Second-generation antipsychotic [1] | H1 antagonism → weight gain; insulin resistance → diabetes; dyslipidaemia | Metabolic syndrome → cardiovascular mortality |
| Inherent disease process involving accelerated aging and medical morbidity [1] | Emerging evidence of accelerated biological aging (telomere shortening, oxidative stress, chronic inflammation) inherent to the disorder itself, independent of lifestyle and medication | Premature cardiovascular, cerebrovascular, and metabolic disease |
Why is cardiovascular disease the biggest killer in schizophrenia? It is the perfect storm: intrinsic metabolic dysregulation + antipsychotic-induced metabolic syndrome + cigarette smoking + sedentary lifestyle + poor nutrition + substance abuse + poor access to healthcare (patients may not report symptoms, may not be taken seriously in medical settings ["diagnostic overshadowing"], and may struggle to navigate healthcare systems). Each factor alone increases cardiovascular risk; together, they are devastating.
The conditions cause profound disruptions in individuals' personality development, social relationships, scholastic and vocational trajectories [1]
Potentially chronic, remitting-relapse course, with significant functional impairment [1]
| Domain | Nature of Impairment | Pathophysiological Basis |
|---|---|---|
| Occupational | Most patients unable to maintain competitive employment (unemployment rates 70–90%); reduced productivity | Cognitive impairment (executive function, processing speed) + negative symptoms (avolition) + positive symptoms during relapse + stigma |
| Educational | Illness onset in late adolescence/early adulthood disrupts education at a critical formational period | Onset during peak educational years → failure to achieve expected qualifications |
| Social/Interpersonal | Social isolation, breakdown of relationships, difficulty forming new connections | Asociality (negative symptom) + paranoid delusions → withdrawal; impaired social cognition (Theory of Mind deficits → inability to read others' intentions and emotions) [1] |
| Self-care | Poor hygiene, poor nutrition, inability to manage finances or housing | Avolition + cognitive impairment → inability to plan and execute daily living activities |
| Caregiver burden | Significant psychological, financial, and social burden on families | Chronic course, high expressed emotion, need for supervision, stigma |
Cognitive impairment is a core feature in schizophrenia, a key determinant of functional outcome, and represents an unmet therapeutic need, not responsive to antipsychotic treatment [1]. This means that even when positive symptoms are well-controlled, patients may remain functionally disabled due to persistent cognitive deficits. This is why cognitive remediation and psychosocial rehabilitation are critical complements to medication.
| Comorbidity | Prevalence | Clinical Significance |
|---|---|---|
| Depression | ~25% develop post-schizophrenia depression [2]; depressive symptoms common throughout illness course | Strongest predictor of suicide; contributes to functional impairment; often mistaken for negative symptoms |
| Substance use disorders | ~50% comorbid (tobacco ~70%, cannabis ~25%, alcohol ~30% [5]) | Worsens psychosis, increases non-adherence, increases violence risk, increases medical morbidity, reduces treatment efficacy |
| Anxiety disorders | ~30–40% | Reduces quality of life; often under-recognised and under-treated |
| OCD | ~12% (much higher than general population ~2%) | May be partly iatrogenic (clozapine can induce/worsen OCD via 5-HT2A/2C antagonism) |
- Patients with schizophrenia have a modestly increased risk of violence compared to the general population, but this is largely mediated by comorbid substance abuse — patients without substance abuse have only marginally elevated risk
- Risk factors: active positive symptoms (persecutory delusions, command hallucinations), substance abuse, non-adherence, history of violence
- Important context: Patients with schizophrenia are far more likely to be victims of violence and exploitation than perpetrators. Stigma from exaggerated media portrayal of violence in schizophrenia is one of the most damaging barriers to care
Catatonia can occur as a complication of schizophrenia itself (discussed in the clinical features section). Malignant catatonia — characterised by fever, autonomic instability, rigidity, and delirium — is a medical emergency with significant mortality if untreated. Treatment is with benzodiazepines (first-line) and/or ECT [2].
2. Complications of Treatment (Iatrogenic)
2A. Antipsychotic Side Effects
These are among the most important complications to know — they directly affect adherence, morbidity, and mortality.
EPS result from D2 receptor blockade in the nigrostriatal pathway, disrupting the balance of the basal ganglia motor circuits.
| Type | Onset | Clinical Features | Mechanism | Treatment |
|---|---|---|---|---|
| Acute dystonia | Hours to days | Sustained involuntary muscle contractions: torticollis, oculogyric crisis, trismus, laryngospasm (can be life-threatening) | Acute D2 blockade in striatum → cholinergic predominance → muscle spasm | IM anticholinergic (benztropine/procyclidine) — rapid response |
| Akathisia | Days to weeks | Subjective inner restlessness, inability to sit still, pacing; intensely distressing; associated with increased suicide risk | Not fully understood; may involve D2 blockade in mesocortical pathway or serotonergic mechanisms | Reduce dose; switch to lower-EPS agent; propranolol (beta-blocker); benzodiazepine |
| Drug-induced parkinsonism | Weeks to months | Bradykinesia, rigidity, resting tremor, shuffling gait, masked facies | D2 blockade in nigrostriatal pathway → dopamine–acetylcholine imbalance in striatum (same mechanism as idiopathic Parkinson's disease, but reversible) | Reduce dose; add anticholinergic (procyclidine); switch to lower-EPS agent |
| Tardive dyskinesia (TD) | Months to years | Involuntary repetitive movements, especially orofacial (lip smacking, tongue protrusion, chewing); may be irreversible | Chronic D2 blockade → compensatory D2 receptor upregulation and supersensitivity → abnormal involuntary movements when blockade is even slightly reduced | Prevention is key (use lowest effective dose, prefer SGAs). Treatment: valbenazine, deutetrabenazine (VMAT2 inhibitors); switch to clozapine (lowest TD risk) |
Why does tardive dyskinesia occur late while parkinsonism occurs early? Parkinsonism is the direct result of D2 blockade (immediate pharmacological effect). TD, by contrast, is a compensatory adaptation — the brain responds to chronic D2 blockade by upregulating and sensitising D2 receptors. Over months–years, this leads to a state of dopaminergic supersensitivity in the nigrostriatal pathway, causing involuntary movements. This is why TD can paradoxically worsen if antipsychotics are abruptly stopped (unmasking the supersensitive receptors).
The most clinically significant long-term complication of second-generation antipsychotics:
| Component | Mechanism | Clinical Impact |
|---|---|---|
| Weight gain | H1 receptor antagonism (appetite stimulation); 5-HT2C antagonism; effects on leptin signalling | Obesity → cardiovascular risk, disability, non-adherence |
| Type 2 diabetes | Insulin resistance (mechanism not fully understood — direct effect on pancreatic β-cells, adipocyte dysfunction) | Diabetic complications; cardiovascular mortality |
| Dyslipidaemia | Elevated triglycerides, elevated LDL, reduced HDL | Atherosclerosis → MI, stroke |
| Hypertension | Weight gain → metabolic syndrome component | Cardiovascular risk |
Worst offenders: clozapine and olanzapine (both +++). Aripiprazole, lurasidone, and ziprasidone are relatively metabolically neutral.
Metabolic syndrome related to 2nd generation antipsychotics is one of the key reasons for the excess mortality in schizophrenia [1][2]. This is why baseline and regular metabolic monitoring (weight, BMI, waist circumference, fasting glucose, lipids, blood pressure) is mandatory for every patient on antipsychotics.
- Mechanism: D2 blockade in the tuberoinfundibular pathway removes the tonic dopamine inhibition of prolactin secretion from the anterior pituitary [2]
- Consequences: Galactorrhoea, amenorrhoea (in women), sexual dysfunction (both sexes), gynaecomastia (in men), osteoporosis (long-term — due to hypogonadism from prolactin-mediated suppression of GnRH)
- Worst offenders: risperidone, paliperidone, amisulpride, sulpiride (all have strong D2 binding but relatively poor blood–brain barrier penetration at tuberoinfundibular level OR particularly potent D2 affinity)
- Minimal/no effect: clozapine, quetiapine, aripiprazole (partial D2 agonist — may actually lower prolactin)
- Mechanism: Blockade of cardiac hERG (IKr) potassium channels → delayed ventricular repolarisation → prolonged QTc interval → risk of torsades de pointes → ventricular fibrillation → sudden cardiac death
- Highest risk: haloperidol (IV > IM > oral), amisulpride, ziprasidone
- Monitoring: baseline ECG before starting antipsychotics; repeat if clinically indicated; QTc > 500ms or increase > 60ms → stop or switch drug
| Aspect | Detail |
|---|---|
| Definition | Life-threatening idiosyncratic reaction to antipsychotic medication (or rapid withdrawal of dopaminergic agents) |
| Mechanism | Severe, acute D2 blockade in the hypothalamus (thermoregulatory centre) and nigrostriatal pathway → autonomic dysfunction + muscle rigidity |
| Clinical features | Tetrad: (1) Hyperthermia (> 38°C, often > 40°C); (2) Lead-pipe rigidity; (3) Autonomic instability (labile BP, tachycardia, diaphoresis); (4) Altered consciousness (confusion → coma) |
| Lab findings | Markedly elevated CK (rhabdomyolysis from sustained rigidity), leucocytosis, elevated LFTs, metabolic acidosis, myoglobinuria |
| Risk factors | High-potency FGAs (haloperidol), rapid dose escalation, IM injection, dehydration, exhaustion, prior NMS episode |
| Management | STOP antipsychotic immediately; supportive care (cooling, IV fluids, cardiovascular support); dantrolene (skeletal muscle relaxant — reduces rigidity and heat production); bromocriptine (dopamine agonist — counteracts D2 blockade); consider ICU transfer |
| Mortality | 5–20% even with treatment; higher with delayed recognition |
| Differential | Malignant catatonia (can look identical — key difference is context: NMS occurs after antipsychotic initiation/dose increase; malignant catatonia occurs in untreated psychosis), serotonin syndrome, malignant hyperthermia |
Why does NMS cause hyperthermia? The hypothalamus is the body's thermostat. It uses dopaminergic signalling to regulate temperature. Severe D2 blockade in the hypothalamus disrupts this regulation → loss of heat dissipation + sustained muscle rigidity (nigrostriatal D2 blockade) generates enormous heat → dangerous hyperthermia. Rhabdomyolysis from the rigidity releases myoglobin → renal failure (a common cause of death).
(Detailed in the management section; summarised here for completeness)
| Complication | Incidence | Mechanism | Monitoring/Management |
|---|---|---|---|
| Agranulocytosis | ~1–2%; highest risk in first 18 weeks | Idiosyncratic immune-mediated granulocyte destruction | Mandatory neutrophil monitoring (weekly × 18w, fortnightly to 1y, monthly thereafter). Stop immediately if neutrophils < 1.5 × 10⁹/L |
| Myocarditis / Cardiomyopathy | ~1–3% for myocarditis; rare for cardiomyopathy | Likely IgE-mediated hypersensitivity (myocarditis) or direct toxic effect (cardiomyopathy) | Baseline and periodic ECG/echocardiography; troponin/CRP if symptoms develop. Highest risk in first months |
| Seizures | Dose-related (risk increases > 600mg/day) | Lowers seizure threshold | Consider prophylactic valproate at high doses |
| Constipation / Ileus | Very common; can be fatal | Antimuscarinic (M1) effects → reduced gut motility → faecal impaction → bowel obstruction/perforation | Proactive bowel regimen; regular monitoring; avoid concurrent anticholinergics |
| Pulmonary embolism | Increased risk | Multifactorial: sedation + obesity + immobility + possible direct pro-coagulant effect | Encourage mobilisation; be vigilant for PE symptoms |
| Sialorrhoea (drooling) | Very common (~30–80%) | Paradoxical: M4 muscarinic partial agonism (despite being antimuscarinic at M1) | Hyoscine patches, ipratropium sublingual, glycopyrrolate |
- Cognitive: Acute post-ictal confusion; anterograde and retrograde amnesia (generally short-lived, days to weeks; bilateral > unilateral placement)
- Medical: Headache, nausea, muscle pain; rare cardiac arrhythmias; extremely rare aspiration
- Mortality: 2–4 per 100,000 (comparable to minor surgery under GA)
3. Complications from the Interaction of Disease, Treatment, and Social Context
- Schizophrenia and related psychoses account for substantial direct and indirect costs to the society [1]:
- The name "schizophrenia" itself carries immense stigma — many Asian countries (including Japan, South Korea, and Hong Kong) have renamed or discussed renaming the disorder (Japan changed to "integration disorder" in 2002)
- Stigma leads to: delayed help-seeking, social exclusion, housing discrimination, employment discrimination, "diagnostic overshadowing" (physical symptoms dismissed as psychiatric), and internalised shame
High risk of relapse [1]. Major risk factor of relapse: non-adherence to medication [1].
Non-adherence (up to 52% [2]) creates a vicious cycle:
Non-adherence → relapse → hospitalisation → medication restarted → side effects → poor adherence → relapse...Each relapse carries risk of:
- Incomplete recovery (the "scar" effect — each episode may leave behind increasing residual deficit)
- Progressive functional decline
- Progressive structural brain changes (grey matter loss) — it is postulated that active psychosis is neurotoxic and delayed treatment leads to irreversible neurological deterioration [2]
- Increased suicide risk during acute relapse
- Social consequences (loss of employment, relationships, housing)
- Patients with chronic schizophrenia are overrepresented in homeless populations and the criminal justice system
- This reflects the combination of functional impairment, substance abuse, medication non-adherence, inadequate community mental health services, and stigma
- Expressed emotion (EE) — critical, hostile, or emotionally over-involved attitudes from family — is both a complication (resulting from caregiver burnout) and a perpetuating factor (increasing relapse risk if EE exposure > 35h/week) [2]
- Caregivers experience increased rates of depression, anxiety, social isolation, financial hardship, and physical health problems
- Family intervention (psychoeducation, support groups, EE reduction) directly addresses this
| Category | Key Complications |
|---|---|
| Disease-related | Suicide (5.6% lifetime; 12× general population; highest in first year of FEP); excess physical morbidity and mortality (lifespan reduced 10–15 years; SMR 2.5); functional impairment (occupational, educational, social, self-care); comorbid psychiatric disorders (depression, substance abuse, anxiety, OCD); violence risk (largely substance-mediated); catatonia / malignant catatonia |
| Treatment-related | EPS (acute dystonia, akathisia, parkinsonism, tardive dyskinesia); metabolic syndrome (weight gain, diabetes, dyslipidaemia — especially olanzapine, clozapine); hyperprolactinaemia (especially risperidone, amisulpride); QTc prolongation (torsades de pointes risk); NMS (life-threatening); clozapine-specific (agranulocytosis, myocarditis, seizures, constipation/ileus, PE) |
| Disease–Treatment–Society interaction | Stigma and discrimination; non-adherence → relapse cycle → progressive decline; homelessness; caregiver burden and high expressed emotion |
High Yield Summary
Suicide: Single largest cause of premature death. Lifetime risk 5.6%. Highest in first year after FEP. Depressed mood is the strongest predictor. Paradoxically, better insight may increase risk.
Excess Mortality: Lifespan reduced 10–15 years (SMR 2.5 in HK). Majority from natural causes, especially cardiovascular disease. Driven by lifestyle, smoking, substance abuse, metabolic syndrome from SGAs, and possibly inherent accelerated aging.
Metabolic Syndrome: The most clinically significant long-term treatment complication. Olanzapine and clozapine are worst offenders. Mandatory baseline and regular metabolic monitoring for all patients on antipsychotics.
EPS: Acute dystonia (hours–days), akathisia (days–weeks), parkinsonism (weeks–months), tardive dyskinesia (months–years, potentially irreversible). All from nigrostriatal D2 blockade. TD is from compensatory receptor upregulation/supersensitivity.
NMS: Life-threatening emergency. Tetrad: hyperthermia, rigidity, autonomic instability, altered consciousness. Stop antipsychotic, give dantrolene + bromocriptine, supportive ICU care.
Clozapine: Agranulocytosis (mandatory neutrophil monitoring), myocarditis, seizures, severe constipation/ileus, PE.
Functional Impairment: Cognitive impairment is the key determinant of functional outcome and represents an unmet therapeutic need (not responsive to antipsychotics). Even when positive symptoms are controlled, patients may remain disabled.
Non-adherence: Up to 52%, the major risk factor for relapse. Each relapse risks incomplete recovery and progressive decline.
Comorbid Substance Abuse: 30% abuse alcohol. Temporarily reduces isolation/anxiety but worsens psychosis, mood, non-compliance, and overall outcome.
Active Recall - Complications of Schizophrenia
References
[1] Lecture slides: GC 170. Schizophrenia and related psychoses.pdf (pp. 3, 4, 11, 12, 13, 23) [2] Senior notes: ryanho-psych.md (sections 6.2, pp. 128–131, 135–138) [5] Lecture slides: GC 161. Alcohol and the Brain From Psychiatric to Neuropsychiatric Perspectives.pdf (p. 44)
High Yield Summary
Definition: Schizophrenia is a chronic neurodevelopmental psychotic disorder characterised by positive symptoms (hallucinations, delusions), negative symptoms (5 A's), disorganisation, cognitive impairment, motor symptoms, and affective disturbance.
Epidemiology: Lifetime risk ~1%; prevalence of all psychotic disorders ~2–3%; M:F = 1.4:1; onset late adolescence/early adulthood; men earlier onset. HK prevalence 2.5%. Incidence varies with urbanicity and migration.
Aetiology — Stress-Vulnerability Model:
- Genetics (80% heritability): Polygenic (dopamine, glutamate, synaptic, immune genes); 22q11.2 deletion → 20–30× risk; MZ concordance ~50%
- Environment: Prenatal (obstetric complications, winter birth, infections, paternal age) + Proximal (cannabis, urbanicity, migration — social defeat hypothesis)
- Gene × environment interaction
Pathophysiology:
- Dopamine hypothesis: Mesolimbic hyper → positive symptoms; Mesocortical hypo → negative/cognitive symptoms
- Glutamate: NMDA hypofunction → excess glutamate → hyperdopaminergia + neurotoxicity
- GABA: Reduced GAD → disinhibition
- Neuropathology: Reduced neuropil, NO gliosis → neurodevelopmental NOT neurodegenerative
- Structural: Reduced GM (temporal, PFC, thalamus, anterior cingulate), increased ventricles, cortical thinning, white matter disconnectivity
Schneider's First Rank Symptoms (SPECTRA): Somatic passivity, Passivity of action/impulse, Echo of thoughts, Commentary/3rd person AVH, Thought insertion/withdrawal/broadcasting, Referential/delusional perception, Audible thoughts
Negative symptoms (5 A's): Avolition, Alogia, Anhedonia, Asociality, Affective flattening
Course: Premorbid → Prodromal (ARMS/CHR) → First Episode Psychosis → Variable longitudinal course (full recovery / residual deficits / chronic)
Delusional disorder: Non-bizarre, systematised, single-themed delusion ≥1 month; preserved functioning; no/minimal hallucinations or negative symptoms; lifetime risk 0.05–0.1%; median onset 46y
High Yield Summary
Approach to psychotic symptoms — always use the diagnostic hierarchy:
- Rule out organic/medical causes first — especially delirium (visual hallucinations, fluctuating consciousness, disorientation), anti-NMDA receptor encephalitis, and metabolic/endocrine conditions
- Rule out substance-induced psychosis — temporal relationship to substance use; urine tox screen; should remit after substance clears
- Distinguish from mood disorders with psychotic features — is psychosis occurring ONLY during mood episodes (mood disorder) or also independently (schizoaffective/schizophrenia)?
- Differentiate among psychotic disorders by duration — brief psychotic disorder ( < 1 month) → schizophreniform (1–6 months) → schizophrenia ( > 6 months)
- Delusional disorder — isolated, non-bizarre, encapsulated delusion; preserved functioning; no/minimal hallucinations or negative symptoms
- Schizotypal PD — attenuated psychotic-like features that are trait-like and enduring; never meets full criteria for schizophrenia
Classic exam pitfalls:
- Manic psychosis misdiagnosed as schizophrenia (look for elevated mood, decreased need for sleep, grandiosity, pressured speech, episodic course)
- Visual hallucinations should prompt organic work-up (delirium, Lewy body dementia, substance-induced)
- Anti-NMDA receptor encephalitis in young women with new-onset psychosis + catatonia + seizures
- Cannabis/methamphetamine-induced psychosis in Hong Kong context
High Yield Summary
Diagnosis of schizophrenia is CLINICAL — investigations exclude secondary causes, not confirm schizophrenia.
DSM-5 Criteria (memorise):
- A: ≥2 of delusions, hallucinations, disorganised speech, disorganised/catatonic behaviour, negative symptoms; at least one must be delusions, hallucinations, or disorganised speech; present for significant portion of ≥1 month
- B: Functional decline
- C: ≥6 months total duration (including prodromal/residual)
- D: Not schizoaffective or mood disorder with psychotic features
- E: Not substance/medical condition
- F: ASD clause
Key ICD-10 vs DSM-5 difference: ICD-10 requires 1 month; DSM-5 requires 6 months. ICD-10 retains subtypes; DSM-5 uses course specifiers.
Duration continuum: Brief psychotic disorder ( < 1 month) → Schizophreniform (1–6 months) → Schizophrenia ( ≥ 6 months)
Schizoaffective key criterion: Psychosis for ≥2 weeks WITHOUT mood episode
Mandatory FEP investigations: FBC, U&E, LFTs, TFTs, Ca²⁺, B12/folate, glucose, lipids, syphilis serology, ESR/CRP, urine drug screen, ECG. CT/MRI brain recommended for all FEP.
Cognitive impairment: Core feature, 1–2 SD below normal, strongest predictor of functional outcome, NOT responsive to antipsychotics — an unmet therapeutic need.
High Yield Summary
Pharmacological Treatment:
- Antipsychotics are the mainstay; D2 receptor antagonism in the mesolimbic pathway reduces positive symptoms
-
80% of FEP patients respond; 70–80% D2 occupancy needed; excessive blockade → EPS
- Maintenance: ≥1–2 years after FEP; non-adherence is the major relapse risk factor → consider depot formulations
- TRS definition: persistent positive symptoms despite 2 adequate antipsychotic trials (≥1 atypical, each 6–8 weeks, adequate dose)
- Clozapine is the ONLY drug with proven superiority in TRS (~30% response rate); also reduces suicidality and aggression
- Clozapine monitoring: neutrophil count weekly × 18 weeks → fortnightly to 1 year → monthly thereafter
- Clozapine serious side effects: agranulocytosis, metabolic syndrome, seizures, myocarditis, constipation/ileus, PE
- If clozapine fails: add another antipsychotic, ECT augmentation, or lamotrigine augmentation
Non-Pharmacological Treatment:
- CBT for residual positive symptoms and comorbid depression/anxiety
- Family therapy to reduce expressed emotions and caregiver burden
- Cognitive remediation for cognitive impairment (unmet therapeutic need — not responsive to antipsychotics)
- Compliance therapy, vocational rehabilitation, social skills training, community case management
- Early intervention (EASY in HK): intensive support for first 3 years of psychosis → reduced suicide, hospitalisation, and default rates
- ECT: reserved for catatonia, severe comorbid depression, and treatment-resistant cases
Prognosis: Chronic, heterogeneous; ~30% TRS, ~20% sustained remission, ~10% suicide, > 50% poor outcome. Poor prognostic factors include male sex, early onset, insidious onset, prolonged DUP, prominent negative symptoms, poor premorbid adjustment, substance abuse, and high EE.
High Yield Summary
Suicide: Single largest cause of premature death. Lifetime risk 5.6%. Highest in first year after FEP. Depressed mood is the strongest predictor. Paradoxically, better insight may increase risk.
Excess Mortality: Lifespan reduced 10–15 years (SMR 2.5 in HK). Majority from natural causes, especially cardiovascular disease. Driven by lifestyle, smoking, substance abuse, metabolic syndrome from SGAs, and possibly inherent accelerated aging.
Metabolic Syndrome: The most clinically significant long-term treatment complication. Olanzapine and clozapine are worst offenders. Mandatory baseline and regular metabolic monitoring for all patients on antipsychotics.
EPS: Acute dystonia (hours–days), akathisia (days–weeks), parkinsonism (weeks–months), tardive dyskinesia (months–years, potentially irreversible). All from nigrostriatal D2 blockade. TD is from compensatory receptor upregulation/supersensitivity.
NMS: Life-threatening emergency. Tetrad: hyperthermia, rigidity, autonomic instability, altered consciousness. Stop antipsychotic, give dantrolene + bromocriptine, supportive ICU care.
Clozapine: Agranulocytosis (mandatory neutrophil monitoring), myocarditis, seizures, severe constipation/ileus, PE.
Functional Impairment: Cognitive impairment is the key determinant of functional outcome and represents an unmet therapeutic need (not responsive to antipsychotics). Even when positive symptoms are controlled, patients may remain disabled.
Non-adherence: Up to 52%, the major risk factor for relapse. Each relapse risks incomplete recovery and progressive decline.
Comorbid Substance Abuse: 30% abuse alcohol. Temporarily reduces isolation/anxiety but worsens psychosis, mood, non-compliance, and overall outcome.
Approach To Psychotic Symptoms
A systematic clinical evaluation of hallucinations, delusions, and disorganized thinking to differentiate primary psychotic disorders from secondary causes such as medical conditions, substance use, and mood disorders.
Misuse Of Alcohol And Alcohol-related Disorders
Misuse of alcohol encompasses a spectrum of maladaptive drinking behaviors ranging from hazardous consumption to alcohol dependence, leading to physical, psychological, and social harm including liver disease, neuropsychiatric disorders, and withdrawal syndromes.